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Epigenetics and chromatin organization
 Multicellular organisms are generated from one single cell that progressively 
divides and ultimately gives rise to a variety of cells, all sharing the same DNA, yet 
displaying different features and morphologies. Therefore the genetic information, 
encoded in the DNA, cannot explain by itself the different phenotypes. How does 
this happen? How is this process regulated? Epigenetic mechanisms are important 
players behind these phenomena.
Epigenetics is typically defined as the study of heritable changes in gene 
expression that are not due to changes in DNA sequence [1, 2]. Epigenetics 
is thus considered a link between genotype and phenotype [3]. With the term 
epigenome we refer to the epigenetic “make-up” across the entire genome. [4] 
Epigenetic regulation controls directly or indirectly several biological processes 
such as transcription, DNA repair, cell differentiation, development, imprinting, X 
inactivation and genome stability [5, 6]. Deregulation of epigenetic control is often 
associated with diseases such as cancer and developmental disorders [6-9].
 In humans, the DNA of a single copy genome is more than two meters long 
and to fit into the volume of a nucleus it has to be tightly packed and organized. The 
basic unit of chromatin is the nucleosome (fig1), which is composed of ~146 base 
pairs (bp) of DNA wrapped around an octamer of four core histones: 1 histone H3-H4 
tetramer and 2 H2A-H2B dimers [10],  defined as the core nucleosome.  
Nuclesome cores are connected by short stretches of linker DNA (~80bp) and 
stabilized by the linker histone H1. Nucleosomes can further be assembled and 
compacted into higher-order structures [11]. Based on the level of compaction, two 
type of chromatin states have been defined: euchromatin and heterochromatin. 
Euchromatin is more loose and permissive, allowing transcriptional activity, whereas 
heterochromatin is more condensed and usually associated to transcriptional 
repression [12]. Epigenetic modifications can alter the compaction of chromatin 
affecting its accessibility or can provide docking sites for other proteins having 
specific recognition domains. Several types of modifications have been described so 
far, among the best understood are DNA methylation [13], histone post translational 
modifications (PTMs) [14, 15], nucleosome positioning [16], exchange of histone 
variants [17] and non-coding RNAs [18].
General Introduction
11
Epigenetic modifications
 Methylation of cytosine is one of the best-studied epigenetic modifications 
in mammals and is well conserved among most organisms. DNA methylation 
can regulate several biological processes such as gene expression, imprinting, 
X-inactivation, genome stability and carcinogenesis. 
 Three decades ago two publications laid the foundations for the definition of 
5-methylcytosine (5mC) as an epigenetic mark [19, 20]. In mammals, DNA methylation 
involves 60-80% of CpG dinucleotides [21], except for those falling in CpG-dense 
regions that are termed CpG islands (CGIs) [22]; these are stretches of ~1kb, 
prevalently un-methylated when situated at transcription start sites of housekeeping 
and developmental regulator genes [23]. In order to understand the function of DNA 
methylation it is very important to study its distribution across the genome. Most of 
the studies in the past focused mainly on methylation of CGIs at the transcription start 
sites of the genes, linking methylation at promoters with transcriptional silencing. 
However, recent genome-wide approaches allowed depicting the entire methylome 
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Figure1: Chromatin organization 
The nucleosome is the core unit of chromatin and consists of DNA wrapped around the histone octamer. 
Each octamer is composed of two copies of the histone proteins H2A, H2B, H3, and H4. Epigenetic mod-
ifications can occur at the DNA level (mC, hmC) and at the histones level and their tails protruding from 
the globular core can be subjected to PTMs. The chain of nucleosomes is then compacted further and 
forms the chromosome. 
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(methylation distribution across the entire genome) at high resolution for several 
species and developmental states, highlighting a complex dynamic [24]. It has 
for instance been shown that while methylation at promoters inhibits transcription 
initiation, methylation within the gene body positively correlates with transcriptional 
activity [25, 26] and aberrant enhancer methylation seem to correlate with altered 
gene expression profiles in cancer [27].
The methylation mark is placed and maintained by DNA methyltransferases 
(DNMTs). Three highly conserved enzymes are responsible for de novo deposition 
and maintenance (DNMT3A/B and DNMT1, respectively) of DNA-methylation and 
they are essential for normal development [28, 29]. The methylation mark can be 
passively removed due to a lack of maintenance during DNA replication resulting 
in a progressive dilution, or it can be actively removed through a de-methylation 
pathway involving Ten-eleven translocation (Tet) enzymes and the DNA-repair 
machinery [30-32]. The breakthrough discovery of the enzymatic activity that 
oxidizes 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and further to 
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) has revolutionized the DNA 
methylation field. Although the advances in next generation sequencing techniques 
have allowed characterizing the 5hmc distribution across the genome, the exact role 
of this modification remains to be elucidated.
 Next to DNA-methylation, histone modifications are the second most studied 
epigenetic marks. The N-terminal histone tails protruding from the nucleosome-core 
are primarily subject to covalent post-translational modifications (PTMs), although 
also the globular core domains can be affected.
 Histone PTMs (see table1), referred as ‘epigenetic’ marks, involve different 
types of aminoacids at multiple positions [15]: most extensively studied are the 
acetylation and methylation of lysine residues; the methylation of arginine residues 
and the phosphorylation of serine and threonine [15, 33] (see Table 1 for a list 
of modified histone residues). In recent years some of these modifications have 
been associated with specific functions and locations in the genome [34, 35](see 
Table 2). It is for instance widely recognized that acetylation is associated with high 
transcriptional activity since it reduces the positive charge on the histones, therefore 
weakening histone-DNA interactions and remodeling higher order chromatin 
structure [36]. The result is a de-compaction of the chromatin structure that favors 
transcriptional activity. Unlike acetylation, histone methylation does not directly alter 
the histones charge, moreover, this modification has an added level of complexity: 
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lysines can be mono-, di- or tri-methylated, whereas arginines can be mono- and 
symmetrically or asymmetrically di-methylated. [37] 
 Despite the fact that the first histone PTMs were discovered in 1964, their 
function in chromatin regulation remained elusive for a long time. To explain the 
complexity coming from the combination of these modifications and to understand their 
role in transcription regulation [38], many researchers in the past have hypothesized 
the existence of a “histone code” [39]. The histone code hypothesis is conceived as 
a sort of language in which multiple histone PTMs act in a sequential or synergistic 
way, causing specific downstream effects and recruiting specific effector proteins. 
Recent discoveries of novel histone PTMs [40], histone variants and the active DNA 
demethylation pathway with its readers [41] revealed a much higher complexity than 
previously envisioned. Therefore the original hypothesis should be revisited trying to 
integrate this new knowledge in a much broader context (reviewed in [42]). Important 
progress in understanding the function of histone PTMs came from the identification 
of the protein complexes that place (writers), remove (erasures), and bind (readers) 
histone modifications [43, 44] (fig2). These enzymes are often part of multisubunit 
complexes. Writers and erasers are enzymes that can place/remove histone PTMs 
such as histone acetyltransferases (HATs) and histone deacetylases (HDAC) or 
histone methyltransferases (HMTs) and histone demethylases (KDM). Readers 
can be recruited to their docking sites through specialized domains: bromodomains 
are specific for acetylated lysine residues, chromodomains for methylated lysines, 
Tudor domains are related to both methylated arginines and lysines and PHD finger 
recognize tri-methylated lysines [45].
Histone residue Type of PTM
Lysines acetylation, methylation, ubiquitination, SUMOylation, 
crotonylation, butyrylation and propionylation
Arginines methylation, citrullination and ADP-ribosylation
Serines/threonines phosphorylation and glycosylation 
Table1 List of histone PTMs types
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H i s t o n e 
modi f ica-
tion 
Putative functions
H3K4me1 Mark of regulatory elements associated with enhancers and other 
distal elements, but also enriched downstream of transcription starts
H3K4me2 Mark of regulatory elements associated with promoters and en-
hancers
H3K4me3 Mark promoters/transcription start sites of active genes 
H3K9ac Mark of active regulatory elements with preference for promoters
H3K9me1 Preference for the 5′ end of genes
H3K9me3 Repressive mark associated with constitutive heterochromatin and 
repetitive elements
H3K27ac Mark of active regulatory elements; distinguishes active enhancers 
and promoters from their inactive counterparts
H3K27me3 Repressive mark established by Polycomb complex activity associ-
ated with repressive domains and silent developmental genes
H3K36me3 Elongation mark associated with transcribed portions of genes, with 
preference downstream of intron 1
H3K79me2 Transcription-associated mark, with preference for 5′ end of genes
H4K20me1 Preference for 5′ end of genes
Table 2 Best-characterized histone PTMs, their localization in the genome and 
with their putative function (modified from [46])
 Nucleosomes are not only responsible of chromatin compaction, but 
they also regulate transcription by physically restricting access to the DNA. The 
nucleosome is a dynamic unit tightly regulated by several multi-subunit complexes 
known as “chromatin modifiers” (discussed above) and “chromatin remodelers” that 
are protein complexes comprising an ATPase domain that catalyze the assembly 
(positioning), the moving (sliding) or the disassembly (eviction) of nucleosomes 
and the exchange of histone variants that differ from canonical histones in their 
composition and functions [17, 47, 48]. Histone variants are expressed and can 
replace canonical histones - for example when nucleosomes are evicted - at any 
time throughout the cell cycle, whereas canonical histones are deposited only 
during replication. Histone variants present structural differences compared to their 
homologues and they confer different structural and functional properties to the 
nucleosome therefore affecting the chromatin dynamics. One of the best-studied 
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remodeling complex is the Nucleosome Remodeling and Histone Deacetylase 
complex (NuRD), which combines amongst others a histone deacetylase activity 
(HDAC1-2) with an ATPase (Mi-2) subunit. Histone chaperones can also regulate 
nucleosome dynamics in collaboration with remodelers by assisting deposition of 
nucleosomes and also by incorporating histones variants. Several research lines 
have revealed how nucleosome positioning is determined by a combination of 
multiple factors rather than a single one, including not only histone modifiers and 
remodelers activity, but also DNA sequence composition and the RNA polymerase II 
(Pol II) activity [49]. 
 Besides covalent modifications and nucleosome remodeling processes, a 
growing research field is exploring the link between non-coding RNAs (ncRNAs) 
and chromatin. NcRNAs are functional RNA molecules that are not translated into 
proteins. NcRNAs involved in epigenetic processes can be divided into two main 
groups: the short ncRNAs (<30 nucleotides) and the long ncRNAs (lncRNA >200 
nucleotides). They are involved in several epigenetic processes as for example 
gene regulation and DNA methylation targeting (imprinting and X-chromosome 
inactivation [50, 51]). One of the first and famous examples of a lncRNA is the 
X-inactive-specific transcript (XIST/Xist)[52], that plays a critical role in inactivation 
of one of the two X-chromosome in females to achieve dosage compensation [53]. 
Xist marks the X-inactivation center by coating it and recruiting silencing factors 
such as Polycomb repressive complex 2 (PRC2)[54], responsible of depositing the 
repressive H3K27me3 mark. The role of lncRNA in epigenetic regulation is mainly 
related to their ability to bind to chromatin-modifying complexes in order to induce 
gene silencing. Genome-wide studies have reported that one of these complexes, 
PRC2, interact with a number of lncRNAs [55], however the molecular basis and 
functional consequence of this interaction are not very well understood.
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Figure2: Epigenetic “players”
Many protein complexes can post translationally modify, recognize and translate the information that 
makes up the epigenome by removing (eraser), depositing (writers) or specifically recognizing (readers) 
these modifications.
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PART II
Epigenetics and development
 In multicellular organisms there are many different cell types, all derived from 
a single fertilized egg. During development epigenetic mechanisms tightly regulate 
the differentiation program to allow the proper temporal expression of specific subset 
of genes, as for instance to silence lineage-specific markers during early embryonic 
stages and shutting down pluripotency genes later on during differentiation [56]. A 
key epigenetic mechanism during this process is DNA methylation: it constitutes 
a barrier that guides and limits differentiation. DNA methylation is highly dynamic 
during the first stages of mammalian development. Two main demethylation waves 
occur during development and are defined as epigenetic reprogramming (fig3): the 
first takes place just after fertilization in the pre-implantation embryo, the second 
wave is erasing DNA methylation of primordial germ cells (PGCs) at embryonic day 
6.5-7.5, before they can proliferate and migrate to the developing gonads [57, 58]. 
Important advances in understanding the dynamics and mechanisms determining 
this epigenetic reprogramming have recently been achieved through genome-
wide high resolution studies [59-64]. At the fertilization stage, a widespread active 
demethylation of the paternal gamete occurs, followed by passive loss of global 
DNA methylation levels up to the blastocyst stage [62], when the inner cell mass 
(ICM) is specified and the embryo is implanted. During this process only few regions 
are protected from demethylation, including parental imprinting control regions (ICR) 
[65]. The first active demethylation wave requires different effector proteins; most 
crucial is Tet3 that oxidizes 5mC to 5hmC, 5fC and 5caC. The oxidized derivatives 
can be passively diluted during following cell divisions or enter other pathways, like 
the base-excision repair (BER)[32, 66, 67]. The passive loss of methylation is mainly 
achieved through exclusion of Dnmt1 [68]and Np95 [61] from the nucleus thereby 
impairing the methylation maintenance.
 After embryo implantation, gastrulation starts and the epiblast is formed, 
followed by a global de novo re-methylation of the genome that contributes to 
lineage restriction [69, 70]. In the re-methylated epiblast PGCs are generated and 
their genome will again be demethylated in a first phase mainly through passive 
demethylation, later on via an active erasure specifically targeting the ICRs and 
germ-line specific genes [63]. However evidence showing direct involvement of Tet 
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proteins in the active demethylation of ICRs during PGCs development is largely 
lacking, but the emerging picture involves both active and passive demethylation 
mechanisms in the epigenetic reprogramming during embryonic development. 
 Histone modifications also contribute to regulation of the developmental 
process: the repressive mark (H3K27me3) and the permissive mark (H3K4me3) were 
found to co-exists at promoters of developmental genes during early development, 
marking the so-called  ‘bivalent’ regions, which keep developmental genes silent but 
at the same time poised for activation [71, 72]. However recent findings from our and 
other lab question the model of Polycomb as main repressive gate during the very 
early stages of development [73, 74]. 
Embryonic stem cells and pluripotency 
 Mouse embryonic stem cells (mESCs) were first derived in 1981[75, 76] and 
they have become a great tool for both basic and translational research. In mammals 
a few days after fertilization the newly developing embryo reaches the blastocyst 
stage, a structure consisting of about 32 cells, organized in two compartment: an 
outer layer called trophectoderm that will contribute to form the extra-embryonic 
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Figure3: DNA methylation reprogramming during development
Two main demethylation waves take place during mammalian development: the first occurs after fertil-
ization, when the paternal pronucleus (in blue) undergoes rapid TET mediated demethylation, followed 
by a passive loss of DNA methylation in the maternal genome (in red). DNA is re-methylated following 
the ICM stage. The second wave of demethylation occurs in Primordial Germ Cells (PGC in green), fol-
lowed by de novo methylation (adapted from [58], with permission of the publisher).
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tissues and an inner layer called the inner cell mass (ICM). Embryonic stem cells 
(ESCs) can be established in vitro from the [77] ICM of a blastocyst: they have the 
ability to differentiate into all cells types (except the extra-embryonic tissues) yet at 
the same time to divide without differentiating, therefore retaining their pluripotent 
potential. One of the most fascinating features of ESC lines is their ability to give 
rise to all tissue types in vitro when placed in the appropriate culture conditions. The 
differentiation potential of ESCs also provides a great model to study early events in 
embryonic development. Moreover, the ease of genetic manipulation and engineering 
has made mESCs one of the favorite model organisms for gene-targeting and 
homologous recombination approaches. Homologous recombination allows deleting 
or altering an endogenous gene and for instance to study how this impacts on its 
pluripotency/differentiation potential. In order to verify the pluripotency of mESCs, 
there are two main assays: the teratoma and chimera assays. The first is performed 
by subcutaneously injecting cultured mESCs into a recipient immunodeficient mouse 
and demonstrating that they will develop into a carcinoma expressing differentiated 
cells from all the three germ layers. The second assay involves injecting mESCs 
into a developing blastocyst and proving that they contribute to all tissues formation 
in a chimeric mouse [77]. The study of the transcription factors sustaining ES cells 
pluripotency has fascinated scientists for years. The first transcription factor described 
as key pluripotency-associated gene was Pou5f1 (Oct4), whose level of expression 
is crucial for pluripotency since both its deletion and over-expression impair self-
renewal [78, 79]. A unique network of pluripotency-associated transcription factors 
has been defined: the core axis includes Oct4, Sox2 and Nanog, in concert with 
a second group of transcription factors, specifically expressed only until the pre-
implantation epiblast stage (reviewed in [80]). Recent advances in deep sequencing 
technologies have widened the picture and additional factors have also been 
identified [81] underlining how the knowledge in this field is in constant evolution.
  
Ground state pluripotency
 Initially described as derived from the mouse blastocyst (day 3.5), ESCs can 
also be successfully isolated from the mouse epiblast (day 4.5) [82]. Mouse ESCs 
were originally cultured in vitro on a “feeder” layer (mitotically inactivated mouse 
embryonic fibroblasts) in a medium supplemented with fetal calf serum (commonly 
referred as serum). Although these culture conditions allowed genetic manipulation 
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and propagation of undifferentiated ESCs, they could only be derived from a single 
mouse strain (129). In order to further refine culture conditions and better understand 
requirements of pluripotency the feeder layer was substituted with the cytokine 
LIF [83, 84]. LIF enhance self-renewal by activating the transcription factor Stat3 
[85, 86], downstream of the activated Janus-associated kinases (JAKs) pathway. 
Another downstream effector of LIF is the MAPK/Erk pathway, which however 
promotes differentiation. Erk is also activated by FGF4, which is highly expressed in 
ESCs. LIF in the absence of serum is not sufficient to sustain pluripotency, as cells 
will differentiate. LIF + serum culturing, however, presents several drawbacks: a 
substantial heterogeneity of cells partially starting to differentiate and a strain barrier 
for ESCs derivation. A screen for chemical compounds that could constitute a valid 
alternative to the standard LIF + serum conditions resulted in the identification of 
2 small inhibitors (defined as “2i”) of MAPK/Erk and GSK3 pathways: PD0325901 
and CH99021, respectively [87]. GSK3 acts on the Wnt/β-catenin pathway and 
its inhibition suppresses ESCs differentiation. The use of 2i (or 2i + LIF) allowed 
propagation of highly homogenous cultures of pluripotent stem cells even at clonal 
density and derivation of ESCs from all strains of mice and even from some rat 
strains [88]. Cells grown in 2i are anchored in a ground state of pluripotency [89]. 
Ground state is a stable pluripotent state, which has a minimum requirement for 
external stimuli, where each single isolated cell is able to form a colony of purely 
undifferentiated cells with the same self-renewal and differentiation potential. Mouse 
ESCs grown in standard serum condition display heterogeneous subpopulation of 
undifferentiated and partially differentiating cells [90]. Expression of pluripotency-
associated markers is also heterogeneous in serum condition [91-93], suggesting 
the co-existence of different sub-populations. Culturing with 2i stabilizes the ground 
state pluripotency and constitutes a powerful tool to study the molecular basis. Cells 
in 2i have a distinct epigenome (see chapter 2) compared to their counterparts grown 
in serum: they display overall reduction in the repressive marks H3K27me3 and 
DNA methylation [94], nevertheless they also show reduced expression of lineage 
specific genes [74], which was thought to be transcriptionally repressed by the 
presence of ‘the missing’ repressive marks. Altogether these results point to a more 
permissive epigenome of mESCs in 2i that might facilitate their progression into any 
lineage specification pathway. It should be kept in mind that release from 2i does 
not delay or alter the differentiation program in vitro therefore upon 2i withdrawal, 
mESCs differentiation recapitulates the embryonic development. It remains to be 
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Figure4: Ground state of pluripotency
Schematic presentation of the signaling pathways involved ground state pluripotency. LIF mainly acts 
via JAK to phosphorylate STAT3 and activate Tcfp2l1 and Klf4, promote pluripotency and self-renewal; 
CHIRON (CH99021) mimics WNT signaling by inhibiting GSK3, PD03 (PD0325901) blocks MEK\ERK 
pathway and downstream differentiation stimuli (adapted from [97], with permission of the publisher).
determined whether it is possible to derive ground state pluripotent ESCs also from 
other mammal species, although first successes have been reported for human 
ESCs [95, 96]. 
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OUTLINE OF THE THESIS
 
 Epigenetic mechanisms fine-tune processes associated with physiological 
and pathological conditions. Application of next generation sequencing (NGS) 
technologies has a great impact on epigenetic studies. It is now possible to couple 
NGS to a number of methods, charting maps of epigenetic modifications distribution 
genome-wide, such as histone modifications, transcription factor binding, RNA 
expression and DNA methylation. Most of these new techniques (e.g. whole-
genome Bisulfite Sequencing (WGBS), Chromatin Immunoprecipitation-Sequencing 
(ChIP-seq), RNA Sequencing (RNA-seq), Chromosome Conformation Capture (3C) 
and DNA accessibility studies) are great tools to investigate the distributions and 
the dynamic changes of epigenetic markers in specific conditions or time frames. 
The emerging datasets can be analyzed and integrated via computational tools, 
resulting in a detailed picture of the biological phenomena under investigation and 
the interplay within different modifications.
 Understanding the molecular mechanisms orchestrating embryonic stem 
cell pluripotency has captured the attention of researchers for many years. One 
of the breakthrough advances in this field was the definition of a specific serum-
free culture condition known as 2i using 2 small molecule inhibitors, allowing the 
derivation and maintenance of homogenous ground-state pluripotent ESCs from all 
mouse strains and for the first time from rats. Raising interest regarding the nature 
of the transcriptional and epigenetic machinery behind ground-state pluripotency 
prompted us to investigate in this direction. Chapter 2 deals with the comparison of 
the transcriptome and epigenome of ground-state pluripotent mouse ESCs cultured 
in 2i compared to standard serum cultures. We performed RNA-seq and ChIP-seq 
for selected histone marks associated with both active and silenced states in both 
culture conditions. We also analyzed the interconvertibility of the profiled epigenetic 
marks and transcriptome adapting the cells from one condition to the other. We show 
that culture conditions strongly affect both the transcriptome and the epigenome of 
mouse ES cells; lineage-affiliated genes were repressed in 2i compared to serum 
condition, suggesting that lineage priming is an effect of culture stimuli rather than 
an intrinsic characteristic of pluripotency. Furthermore, H3K27me3 was reduced at 
promoters of repressed genes, suggesting that Polycomb is not the main repressive 
factor.
General Introduction
23
 DNA  methylation is one of the most extensively studied epigenetic 
modification involved in silencing. One of the basic question remained: how is this 
mark read by the cell and translated into an action? In that light, readers of DNA-
methylation are key as they translate the epigenetic modification. Several families 
of DNA methylation readers have been characterized. Methyl-CpG binding domain 
proteins (MBDs) are among the first readers to be discovered already decades 
ago, however, their genome-wide distribution remained elusive until recent years. 
Chapter 3 reviews the state of art in research of genome-wide binding profiles and 
what can be learned from them for two of the MBD family members: MBD2 and 
MBD3. 
Chapter 4 focus specifically on MBD2, a component of the Mi2/NuRD complex. 
At the outset of the thesis, genome-wide profiles were not available in part due to 
the lack of good quality antibodies for ChIP-seq. Therefore, we opted for a tagging 
approach and optimized ChIP conditions using a double crosslinking strategy. A 
MBD2/NuRD component, ZMYND8, is the focus of Chapter 5 , where we used 
quantitative mass-spectrometry to characterize the interaction between ZMYND8 
and the NuRD complex. Furthermore, we investigated the genome-wide localization 
of ZMYND8 in order to gain insight into its putative role as recruiter of NuRD to 
hypomethylated loci as previously reported.
In Chapter 6 the data presented in this thesis are summarized and discussed in the 
light of recent studies, together with the directions for future research.   
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SUMMARY
Mouse embryonic stem (ES) cells grown in serum exhibit greater heterogeneity in 
morphology and expression of pluripotency factors than ES cells cultured in defined 
medium with inhibitors of two kinases (Mek and GSK3), a condition known as ‘‘2i’’ 
postulated to establish a naive ground state. We show that the transcriptome and 
epigenome profiles of serum- and 2i-grown ES cells are distinct. 2i treated cells 
exhibit lower expression of lineage affiliated genes, reduced prevalence at promot-
ers of the repressive histone modification H3K27me3, and fewer bivalent domains, 
which are thought to mark genes poised for either up- or downregulation. Nonethe-
less, serum- and 2i-grown ES cells have similar differentiation potential. Precocious 
transcription of developmental genes in 2i is restrained by RNA polymerase II pro-
moter-proximal pausing. These findings suggest that transcriptional potentiation and 
a permissive chromatin context characterize the ground state and that exit from it 
may not require a metastable intermediate or multilineage priming.
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INTRODUCTION
 Mouse embryonic stem (ES) cells are characterized by the potency to gen-
erate all somatic and germline lineages in vitro and in chimaeric embryos [1]. The 
nature of the transcriptional and epigenetic machinery that maintains this potential 
throughout massive in vitro expansion has been the subject of intense investigation 
[2]. Interest is further heightened by appreciation that knowledge of the molecular 
underpinning of mouse ES cells may enable derivation of equivalent human naïve 
pluripotent stem cells [3].
 ES cells are described as transcriptionally hyperactive [4]. Promiscuous 
transcription has been suggested to constitute a platform for lineage specification 
[5]. Taken together with the observation that several pluripotency factors are ex-
pressed heterogeneously [6-8] this has given rise to the notion that pluripotency 
may inherently be a metastable condition [9-11]. Attention has also been drawn to 
co-localisation at many promoters of histone 3 lysine 4 trimethylation (H3K4me3), 
associated with transcriptional activation, and histone 3 lysine 27 trimethylation 
(H3K27me3), linked with repression [12-14]. These bivalent domains are posited 
to be poised for either up- or down-regulation, providing an epigenetic blueprint for 
lineage determination.
 The preceding views are based on analyses of ES cells cultured in serum 
and therefore subject to uncontrolled multi-factorial perturbations. It is now possible 
to derive and maintain pluripotent mouse ES cells without serum factors by using 
two small molecule kinase inhibitors (2i) in combination with the cytokine leukaemia 
inhibitory factor (LIF) [15]. The 2i inhibitors, PD0325901 and CHIR99021, selective-
ly target mitogen-activated protein kinase kinase (Mek) and glycogen synthase ki-
nase-3 (Gsk3), respectively. The inhibitors shield pluripotent cells from differentiation 
triggers: fibroblast growth factor-4 stimulation of the Mek-Erk pathway, and endoge-
nous repressor activity of Tcf3 [16, 17]. Use of 2i has enabled derivation of germline 
competent ES cells from all mouse strains tested and for the first time from rats [10, 
18-21]. 2i thus provides a better-tuned environment for rodent ES cells. Indeed, the 
mosaic expression of pluripotency factors observed in serum is effectively eliminated 
in 2i [17]. Furthermore, culture in 2i may mimic the environment in the mature mouse 
inner cell mass (ICM) where the fibroblast growth factor receptor is downregulated in 
the epiblast [22].
 Here we applied massively parallel sequencing technology to characterise 
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the global transcriptome and to map selected histone modifications in naïve mouse 
ES cells maintained in 2i compared with heterogeneous cultures in serum.
RESULTS
Transcriptome analysis
 Three ES cell lines derived and maintained in 2i plus LIF (“2i” ES cells) 
were compared with three ES cell lines established and cultured in serum plus LIF 
(“serum” ES cells) (Tables S1 and S2). Each cell line is functionally pluripotent as 
demonstrated by competence to generate high contribution chimaeras with germline 
transmission. Expression values from RNA-seq data were calculated by quantify-
ing the number of sequence reads for each gene using standardized RPKM val-
ues (Reads Per Kilobase of exon model per Million mapped sequence reads). This 
comparison showed that 1489 genes have > 2-fold higher transcript abundance in 
2i (p-value <0.2), while 1947 genes exhibit > 2-fold higher expression in serum (Fig-
ure 1A). Moreover, 160 genes expressed in 2i (RPKM > 0.5), were silent in serum 
(RPKM < 0.2) and 461 genes were expressed only in serum (Figure S1A, Table S3). 
The majority of categorised stem cell maintenance genes (GO:0019827, SCM) are 
transcribed to similar levels in 2i and serum, including validated core pluripotency 
factors, Pou5f1, Nanog, Sox2, Esrrb, Klf2, Klf4 and Tbx3 (Figure 1B, Figure S1B). 
Nine SCM genes are more highly expressed in 2i (Figure 1B, Figure S1C). Of these, 
only Tcl1 has been implicated as a regulator of self-renewal [23] and while this tran-
script is more abundant in 2i, it is also well expressed in serum. In serum, 16 SCM 
genes showed higher expression. Factors in this group, such as c-Myc and the Id 
proteins, are known to be induced by Erk signalling and by serum. They may confer 
additional robustness to the pluripotent state to counter differentiation stimuli [24]. 
Interestingly, several of these genes are induced when ICM cells are explanted in 
medium containing serum (Figure S1D; [25]).
 Functional annotation clustering of differentially expressed genes by Gene 
Ontology (GO; PANTHER) and Pathway (KEGG) analysis (Figure 1C) revealed that 
genes upregulated in 2i are highly enriched for terms associated with metabolic 
processes. This is probably in part a direct consequence of inhibition of Mek and 
Gsk3 and the absence of serum constituents. Reduced c-Myc may further affect 
metabolic networks. Major differences are also apparent for genes involved in cell 
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cycle regulation. Proliferation is similar in the two conditions [15], however, reflecting 
the absence of G1 restriction in ES cells.
 Upregulated genes in serum are significantly enriched for GO terms linked 
to developmental processes, particularly ectoderm and mesoderm germ layer spec-
ification (Figure 1C). Genes such as Pax6, T (Brachyury) and Runx1, show very low 
or undetectable expression in 2i but appreciable transcription in serum (Figure 1D). 
Other ectoderm and mesoderm marker genes like Runx3, Sox18, Cdx4 and Tal1 are 
also activated in serum, although only to low levels. In contrast, several genes as-
sociated with the germline or with endoderm are expressed at similar levels in both 
conditions.
 ES cells maintained in 2i are morphologically uniform and rather homoge-
neous in expression of pluripotency regulators [26]. In contrast, serum ES cells are 
heterogeneous in morphology (Figure S2A) and expression of factors such as Nanog, 
Rex1, Stella and Klf4 ([6, 7, 11]; Figure S2B). In serum, ES cells with a mono-allelic 
GFP knock-in at the Rex1 (Zfp42) locus comprise GFP positive and negative pop-
ulations that can be separated by flow cytometry (Figure S2C; [17]). These popula-
tions are functionally distinct. Rex1GFP-positive cells plated in serum generate col-
onies of undifferentiated cells while Rex1GFP-negative cells produce predominantly 
small, differentiated colonies (Figure S2D). On plating in 2i, Rex1-positive cells yield 
>10-fold more ES cell colonies than Rex1-negative cells. Rex1-negative cells have 
therefore largely lost clonogenic self-renewal capacity. Consistent with this, although 
they express Oct4, they lack Nanog and Klf4 (Figure S2E). All Nanog positive and 
almost all Klf4 positive cells are within the Rex1GFP-positive fraction. Expression is 
still mosaic within this population, reflecting transcriptional fluctuation ([6, 27]; Fig-
ure S2E). In contrast, ES cells in 2i are uniformly positive for Rex1, Klf4 and Nanog 
([26]; Figure S2B). We examined the transcriptome of the Rex1-positive fraction in 
serum and found a similar increased expression of a subset of SCM genes as bulk 
ES cells (Figure 1B). Some ectoderm and mesoderm associated genes were also 
upregulated compared with 2i ES cells but others showed little induction (Figure 1D). 
In general, differentiation genes were more highly expressed in Rex1GFP-low cells 
(Figures S2F-S2H). Nonetheless, transcriptomes of the Rex1-positive compartment 
in serum shows many differences from 2i ES cells (Figure S2I). Notably, many genes 
that show higher expression in 2i are not upregulated in Rex1 positive serum ES 
cells (Figure 1B). Therefore it is unlikely that a sub-population of serum cells persist 
in an equivalent state to 2i.
38
Chapter 2
A 
Fig 1 
B 
C 
Higher 2i Higher serum 
Ectoderm (Ecto)Mesoderm Germ- 
line 
Endoderm 
R
P
K
M
 (
lo
g)
 
D 
Higher 2i (1489) 
Higher serum (1947) L
og
2 
fo
ld
 c
ha
ng
e 
Higher serum Higher 2i Similar 2i vs serum (subset) 
RPKM (log) 
39
The transcriptome and epigenome of ground state pluripotency
Transcriptome interconversion
 To assess if the distinct gene expression patterns in 2i and serum represent 
“fixed” transcriptional states, we transferred 2i cells to serum and vice versa. Within 
2-3 passages cultures adopted morphological characteristics of the new condition. 
We carried out RNA-seq analyses after 8 passages. Most of the SCM genes that 
showed lower expression in 2i were upregulated in serum, while transcripts elevat-
ed in 2i were downregulated (Figure 2A red dots and black squares, respectively). 
Reciprocal behaviour was observed when serum cells were transferred to 2i (Figure 
2B). Furthermore, genes involved in ectoderm and mesoderm germ layer specifica-
tion were broadly upregulated following transfer of 2i cells to serum and the reverse 
transcriptional changes were observed when serum cells were passaged in 2i (Fig-
ures 2A and 2B, blue stars). Typical examples are shown in Figure 2C. Irrespective 
of the direction of exchange between 2i and serum, 818 genes were expressed 
more highly (>2-fold) in 2i and 1209 showed higher levels in serum (Figure 2D). GO 
classification identified developmental genes and cell cycle control genes as highly 
enriched upon transfer to serum, while genes upregulated in 2i were mainly associ-
ated with metabolic categories (Figure 2E). The reciprocity in transcriptome changes 
demonstrates that the transcriptional profiles are interconvertible.
Figure 1. (previous page) Transcriptome profiling of ES cells in 2i and serum.
(A) Fold change (log2 values) in transcript level of all genes in 2i versus serum. Gene expression values 
of three ES cells lines derived and maintained in either 2i (TNGA, NOD_male and NOD_female) or serum 
(E14, XT67E1 and RGD2) were averaged, after which ratios were calculated. A 2-fold change is indicated 
by the dotted line. The corresponding heatmap is shown at the bottom. For the remaining analysis, an 
extra constraint for differential gene expression was set by a p value < 0.2 (Student t-test). (B) RNA-seq 
levels of a selection of pluripotency, self-renewal and stem cell markers for 2i and serum ES cells as 
shown in (A). Expression values for the Rex1-positive serum ES cell population as collected by FACS (Fi-
gure S2C) are included. (C) Functional annotation analysis of the differentially expressed genes between 
2i and serum ES cells. (D) Transcript level of genes associated with the various germ layers. (See also 
Figure S1, Figure S2, Table S2, and Table S3.)
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Figure 2. Expression profiles of 2i and serum ES cells are interconvertible.
Comparison of expression of pluripotency and lineage-specific genes (as shown in Figure 1B and 1D) 
for TNGA cells adapted from 2i to serum (A)   and E14 adapted from serum to 2i (B) . (C)  Typical 
examples of genes that show transcriptional interconvertibility. (D)  Number of genes that show inter-
convertibility (>2 fold difference between both 2i and serum conditions). (E)  Functional analysis of the 
differential genes shown in (D) , the genes consistently higher in either 2i or serum. 
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Histone modification profiles
 
 We performed chromatin immunoprecipitation and deep sequencing (ChIP-
seq) to analyse post-translational histone modifications: H3K4me3 and H3K36me3 
associated with active promoters and transcribed genes, respectively; H3K27me3 
linked to silencing; H3K9me3 associated with constitutive heterochromatin and 
imprinted genes (Table S1). We also analysed the polycomb repressor complex 2 
(PRC2) component Ezh2 that methylates H3K27 [28].
 Determination of average profiles over 2000 genes that are most highly ex-
pressed in both conditions (Figure 3A, Figure S3A) revealed conventional distribu-
tion of H3K4me3 on active promoters, and of H3K36me3 extending over the coding 
body. The H3K9me3 ChIP-seq state maps of 2i and serum cells were nearly identi-
cal with prominent deposits over satellites and imprinted genes (Figures S3B-S3E). 
As expected, the H3K27me3 mark is absent from actively transcribed loci (Figure 
3B). It appears to be mutually exclusive with H3K36me3 (Figures 3A, 3B and 3C, 
Figure S3F), in line with recent biochemical data showing that PRC2 activity is in-
hibited by active marks including H3K36me3 [29]. However, H3K27me3 is widely 
deposited over intergenic regions and inactive genes at levels appreciably higher 
than random distribution. This lawn of H3K27me3 is qualitatively and quantitatively 
similar in 2i and serum ES cells (Figure 3C). A pronounced difference is apparent 
only at promoters of lowly expressed genes (Figure 3B). The averaged profile of 
these promoters showed markedly less H3K27me3 in 2i than in serum. This was not 
reflected in any overall increase in expression (Figure S3H). Three independent 2i 
ES cell lines exhibited a significantly reduced level of H3K27me3 at the promoters 
of poorly- or non-expressed genes compared with serum cultures (Figure 3D). To 
investigate whether differences in H3K27me3 deposition reflected heterogeneity in 
serum, we performed H3K27me3 ChIP-seq on Rex1-positive and Rex1-negative 
serum sub-populations. Intriguingly, the H3K27me3 signals were very similar, each 
resembling the total serum ES cell population (Figure 3E).
 Intensity plots covering a region of 5 kb up- and downstream of all promot-
ers that are decorated with H3K27me3 in serum demonstrate the major reduction 
in H3K27me3 in 2i cells (Figure 3F). Ezh2 levels were also diminished at these lo-
cations in 2i. In either condition, the H3K27me3 pattern follows a camelback profile 
with a depleted region around the transcriptional start site. Ezh2 appears as a sin-
gle peak centred on this trough. Representative examples of differential H3K27me3 
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profiles are shown in Figure 3G (Figure S3I shows the PCR validation). The Gata6, 
Pax9 and Lhx1 genes are barely expressed in either 2i or serum but in all cases 
the H3K27me3 signal around the promoter is selectively and greatly reduced in 2i. 
For the Lhx1 locus, adjacent Aatf provides a contrasting example of a gene that is 
productively transcribed in both 2i and serum and remains devoid of H3K27me3 in 
either condition.
 Given the interchangeable transcriptome profiles between 2i and serum, we 
examined the epigenomic landscape in ES cells transferred between the two condi-
tions. Cells taken from 2i into serum acquired substantially elevated H3K27me3 at 
H3K27me3 associated promoters (Figure 3H), the Hox clusters (Figure S4A) and 
many other loci (Figure S4B). Conversely, serum ES cells transferred into 2i dis-
played diminished H3K27me3 at these loci. Ezh2 and Suz12 localisation similarly 
switched between culture conditions (Figure 3H, Figures S4A and S4B). Therefore 
these epigenomic states are interconvertible.
 H3K27me3 was reduced by between 63-75% over all Hox clusters in 2i 
(Figure 3G, Figure S4A). The Hoxc locus follows this pattern, but with a distinctive 
variation; in the Hoxc13-c12 region H3K27me3 deposition is lost entirely. This region 
(boxed in Figure 3G) is transcribed only in 2i. Strand specific RNA-seq profiling after 
rRNA depletion revealed that two non-overlapping transcripts on the reverse and 
forward strand (both boxed in Figure S4C, left). These novel ncRNAs are distinct 
from the HOTAIR ncRNA located between HOXC11-12 in human [30]. Consistent 
with recent findings [31] we detected multiple novel and known ncRNAs. Many of 
these, such as H19, showed differential expression between 2i and serum (Figure 
S4C, Table S4).
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Global redistribution of H3K27me3
 We computed the number of H3K27me3 reads over non-repetitive re-
gions and plotted the frequency of occurrence and the genomic location. In 2i, high 
H3K27me3 deposition is scarce with very little enrichment at promoters. In contrast, 
in serum H3K27me3 is elevated at many genomic locations, 60-65% of which are 
promoters (Figures 4A and 4B). In 2i H3K27me3 is somewhat reduced over LINE 
repeats (Figure 4C). This is more than offset, however, by much higher levels over 
satellites. Immunoblotting showed that the total cellular level of H3K27me3 is com-
parable in 2i and serum (Figure 4D), confirming that the differences at promoters are 
not secondary to a general reduction in H3K27me3 deposition in 2i.
 H3K27me3 is deposited by PRC2, and facilitates recruitment of the PRC1 
complex. Transcripts of PRC2 and PRC1 subunits were present at similar levels in 
2i and serum (Figure S5A). Transcripts for the H3K27me3 demethylases Kdm6a and 
Kdm6b (also known as Utx and Jmjd3) were also comparable. Ezh2 immunoblotting 
indicates slightly lower protein in 2i than in serum (Figure S5B). However, phosphor-
ylation of Ezh2 at Thr345, reported to be important for PRC2 recruitment [32], is sim-
ilar (Figure S5C). Collectively these data suggest that the difference in H3K27me3 
occupancy at silent promoters in 2i is not primarily attributable to reduced expression 
of polycomb, nor to altered demethylase expression.
Figure 3. (previous page) H3K27me3 is greatly diminished at promoters of silent genes and at Hox 
clusters in 2i.(A) Average H3K4me3 and H3K36me3 profiles of the 2000 most active (left plots) and 2000 
silent genes (right plots) from -10kb to +10kb at the transcription start site and the transcription stop. The 
negative control (genomic DNA) is shown in Figure S3B. (B)  Average profiles of H3K27me3 and Ezh2 
associated with silencing as in (A) Figure S3G shows a biological replicate analysis for the H3K27me3 
profiles of TNGA 2i ES cells (C) Typical example of H3K27me3 and H3K36me3 (dense setting) profiles. 
(D)  H3K27me3 profiling for three different cell lines maintained and derived in either 2i or serum, as in 
(B) H3K27me3 profiles were generated for TNGA, NOD_male and NOD_female ES cells in 2i, and E14, 
HM1 and RGD2 ES cells in serum. (E)  As in (B) : H3K27me3 profiling in Rex1-positive and Rex1-negati-
ve serum ES cells. (F)  H3K27me3 and Ezh2 intensity plots of all promoters containing H3K27me3 at >3 
fold over random distribution in at least one of the conditions TNGA-2i or E14-serum. 3870 promoters are 
depicted in rows on the y-axis. (G)  Typical examples showing H3K27me3 reduction in 2i as compared to 
serum. (H)  As in (F) : Promoter profiles for 2i ES cells adapted to serum, and vice versa. Average profiles 
are plotted in the middle (gray: 2i; black: serum).See also Figure S3, Figure S4, and Table S4. 
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Bivalency 
 Promoters that are marked by H3K27me3 may also display H3K4me3. Such 
bivalent genes are thought to be poised for activation [12, 13, 33]. We binned and 
ranked promoters according to the read density for H3K27me3 (Figure 5A) mea-
sured in serum and assessed whether bivalency is preserved in naïve ES cells. 
Applying similar filters and thresholds as used by [33], we classified some 3000 
genes as bivalent in serum (Figure 5B (upper panel), Table S5). This group is not 
spared the reduced deposition of H3K27me3 in 2i. Consequently many fall below the 
threshold and less than 1000 qualify as bivalent (Figure 5B (lower panel)). Intensity 
plots show the general and pronounced diminution in H3K27me3 deposition while 
H3K4me3 is only slightly altered (Figure 5C). Figure S6A documents the levels of 
mRNA, H3K27me3 and H3K4me3 in 2i versus serum. Notably, the profiles intercon-
vert upon switching cells between serum and 2i (Figures S6B and S6C).
 In both serum and 2i, the bivalent genes are enriched for involvement in de-
velopmental processes. Representative examples are the mesoderm specification 
marker Hey2 and the ectodermal Metrnl (Figure 5D). Transcripts are barely detect-
able in 2i, although H3K4me3 is present and H3K27me3 is low. In serum, tran-
scription is slightly upregulated even though the promoters show a broad gaining of 
H3K27me3. A significant proportion of genes with bivalent promoter marking (31%) 
exhibit only background transcription in either condition (RPKM < 0.2). However, 
14% of the bivalent genes are serum specific (RPKM > 0.5 in serum; RPKM < 0.2 in 
2i), while a minor fraction (4%) is expressed only in 2i.
 In either serum or 2i H3K27me3 does not co-localise precisely with H3K4me3 
but accumulates on either sides of the H3K4me3 peak at the transcription start site 
(Figure 5C). This is consistent with observations that targets of TrxG proteins, that 
methylate H3K4, show reduced H3K27 methylation [34, 35], and that PRC2 activity 
is inhibited by active marks including H3K4me3 [29]. Strikingly RNA polymerase II 
(Pol II) is evident over transcription start sites at higher levels in 2i than in serum 
(Figure 5C), suggestive of promoter proximal pausing.
Influence of c-Myc
 c-Myc is implicated in pause release [36]. We previously noted a very low 
level of c-Myc protein in 2i [15]. The RNA-seq data show that c-Myc mRNA is 40 to 
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50-fold lower in 2i than in serum and N-myc and L-myc are also reduced (Figure 1B). 
We analysed c-Myc targets that are upregulated in serum (Figure 6A, Figure S7A). 
Averaged profiles show that promoters of these genes are loaded with H3K4me3 
and Pol II in 2i. In serum, Pol II is reduced at the promoters and increased over cod-
ing bodies. The Pol II travelling ratio is accordingly increased (Figure 6B), consistent 
with c-Myc acting as a pause release factor in serum. Typical examples are Npm1 
and Ncl (Figure 6C).
 We assessed to what extent global differences in transcriptome between 
2i and serum might be related to c-myc. Several differentially expressed genes are 
c-Myc targets, notably cell cycle regulators (Figures S7B and S7C). These include 
cdk/cyclinD components that are positively regulated by Myc and are increased in 
serum, and conversely cell cycle inhibitors, p16(Ink4A), p19(Arf) and p21, that are 
repressed by Myc and upregulated in 2i (Figure S7D). Overall, however, direct c-Myc 
targets as determined by [37] represent less than 15% of genes differentially ex-
pressed between 2i and serum (Figure 6D). Furthermore, gene ontology classifi-
cation of c-Myc targets upregulated in serum did not identify categories associated 
with developmental processes. Therefore Myc is unlikely to be a major determinant 
of differential expression and metastability.
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Figure 4. Localisation and quantification of H3K27me3 in 2i and serum.
(A) Binning of H3K27me3 enriched regions in 2i and serum according to tag densities per peak (in reads/
kb). The calculated genomic background is 5 reads/kb per 10 million mapped sequence reads (see expe-
rimental procedures). (B) Genomic distribution of H3K27me3 peaks in 2i (left) or serum (right) per bin as 
shown in (A). (C) Percentage of H3K27me3 reads present in the major repeat categories. (D) Western 
blot analysis of histone modifications in total cell extracts. See also Figure S5.
Figure 5. (next page)  Bivalency in 2i and serum.
(A) (blue) H3K27me3 and H3K4me3 intensity plots at the promoters of all genes (sum of reads), ranked 
on highest to lowest H3K27me3 values in TNGA-serum. (gray) Density plot of bivalent genes identified 
by Mikkelsen et al. (2007; “M”). 
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RNA polymerase II pausing
 We evaluated the average histone modification profile of all genes that 
change expression more than two fold in 2i versus serum. Genes upregulated in 2i 
show the expected increased H3K4me3 deposition at the promoter and higher levels 
of H3K36me3 over the coding body than in serum (Figure 6E, Figure S7E). The re-
pressive mark H3K27me3 is correspondingly reduced. Upregulated genes in serum 
also show an increase in H3K36me3 over the coding body, but in general do not 
exhibit a significant change in H3K4me3 deposition. More remarkably, on average 
they show increased H3K27me3.
 We then examined Pol II occupancy at these two groups of genes. This 
showed that up-regulation in 2i is reflected in elevated Pol II over the transcriptional 
start site as well as the coding body (Figure 6F (left)). In contrast, genes upreg-
ulated in serum showed increased Pol II over the coding body but also on aver-
age a reduced signal at the start site (Figure 6F (right)). These features indicate 
that transcriptional elongation at genes already loaded with Pol II is a widespread 
mechanism of up-regulation in serum. RNA-seq data reveal no overt differences in 
expression of pTEFb components or known regulators of pausing between 2i and 
serum (Figure S7F). Regulation at the protein level may therefore control differential 
promoter proximal pause release in naïve and metastable ES cells.
Multilineage differentiation 
 
 ES cells maintained in either 2i or serum can colonize the mouse embryo, 
demonstrating that they are functionally pluripotent. However, they differ markedly 
in transcription of ectodermal and mesodermal specification genes. The precocious 
transcription of lineage associated genes, often termed lineage priming [38], is pos-
ited to poise stem cells for differentiation. We therefore compared the differentiation 
behaviour of ES cells maintained in 2i or serum. We first used a monolayer neural 
induction protocol with Sox1GFP reporter ES cells to quantify differentiation [39]. 
Although ES cells maintained in serum express several neuroectodermal genes, 
they were less efficient in generating Sox1GFP positive neural precursors than ES 
cells taken from 2i (Figure 7A). This could be due to the presence of cells already 
biased towards a mesodermal fate in serum. Clearly pre-expression of neural genes 
in serum does not predispose to this fate. We then used Rex1GFP fractionation to 
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compare ES cell sub-populations in serum with 2i ES cells in embryoid body differ-
entiation. Rex1GFP-positive cells from serum showed similar behaviour to 2i cells 
(Figure 7B). Down-regulation of Nanog and Rex1 was followed by up-regulation of 
the post-implantation epiblast marker Fgf5. From 3 days onwards Fgf5 was down-
regulated and first Brachyury (although very minor as compared to the Rex1-nega-
tive cells), then mesoderm and endoderm lineage markers Tbx6, Cxcr4, Sox17 and 
Gata4 appeared. This order is consistent with the developmental progression from 
blastocyst to gastrulation. In contrast, Rex1GFP-negative cells exhibit accelerated 
up-regulation of Brachyury and Tbx6 consistent with mesodermal priming to meso-
derm and their loss of self-renewal.
Figure 6. (next page) RNA polymerase II pausing in naïve ES cells.
(A) Averaged Pol II at promoters of Myc-targets upregulated in serum. The top corner values represent 
the average log2 fold difference of the individual data points, and the variance, between 2i and serum. 
(B) Pol II travelling ratio (a quantification of pause release) of the Myc targets upregulated in serum. (C) 
Typical examples of two Myc target genes showing pause release of Pol II. (D) Percentage of Myc targets 
among all genes (left), or among the genes higher (>2 fold change) in serum or 2i (right). (E) Averaged 
profiles of the promoter region of genes that are more highly expressed in 2i (left) or serum (right). (F) 
Averaged Pol II profiles for the same gene groups as in (E). See also Figure S7. 
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Figure 7. Differentiation kinetics/potential of 2i and serum ES cells.
(A) Monolayer neural differentiation of Sox1-GFP ES cells maintained in either 2i or serum. (B) 
Embryoid body differentiation of cells maintained in 2i, and of Rex1-positive and Rex1-negative serum 
ES cells as sorted by FACS (Figure S2C). Expression levels were determined by RT-qPCR. 
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DISCUSSION
 High resolution genome-wide analyses have revealed that culture environ-
ments impose distinctive transcriptional and epigenomic properties on mouse ES 
cells. In total some 13,000 genes are transcribed at above background levels (>0.2 
RPKM). The corollary of this is that around half of genes are effectively inactive. 
Therefore, undifferentiated ES cells do not show promiscuous gene expression or 
global transcriptional hyperactivity [4]. Nonetheless, the pluripotent transcriptome 
displays a broad bandwidth, with more than 25% of active genes showing 2-fold or 
greater differences between 2i and serum. Around 1400 genes, predominantly as-
sociated with metabolic processes, are upregulated in 2i. In contrast KEGG analysis 
points to decreased expression in 2i of components that might drive differentiation, 
such as cell communication, MAPK and TGFb pathways. Most strikingly, many ec-
todermal and mesodermal specification genes that exhibit significant expression in 
serum are repressed in 2i. Low to absent lineage-affiliated gene expression indi-
cates that multi-lineage priming is not an intrinsic feature of self-renewing ES cells. 
Up-regulation of such genes in serum suggests that metastability may be an induced 
condition rather than an inherent property of pluripotent cells.
Some endodermal genes such as Hex retain low-level expression in 2i. This may re-
flect the potential to generate extraembryonic endoderm [40]. High levels of Prdm14, 
which has been reported to repress extraembyronic endoderm transcription factors 
[41], may prevent full activation of this programme.
 Importantly, ES cells transferred between 2i and serum switch their tran-
scriptional profile. Thus a significant component of previously described ES cell sig-
natures reflects an induced serum response. However, critical pluripotency factors 
are transcribed at similar or only slightly higher levels in 2i. The pluripotency repres-
sors Tcf3 [17] and components of the NuRD complex [42] are also expressed at 
comparable levels. A subset of SCM factors are specifically upregulated in serum, 
including the Id genes that are induced by BMPs or fibronectin and are thought to 
directly counter the effects of Erk activation [39]. Increased Eras, shown to be im-
portant for ES cell propagation [43], and factors such as Sall4, Lin28 and Utf1, may 
also contribute to reinforcing self-renewal in the face of differentiation stimuli.
 The conflict between pluripotency factors and lineage specifiers results in 
metastability and incipient differentiation in serum. It is suggested that this “precari-
ous balance” [5] may reflect the circumstance in egg cylinder epiblast cells. Howev-
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er, serum stimulation is an artefactual scenario that may be far from representative 
of the spatiotemporal precision of inductive stimuli in the embryo. To access post-im-
plantation definitive lineages ES cells should pass through a phase equivalent to egg 
cylinder epiblast [44]. Consistent with this, Fgf5 is upregulated in embryoid bodies 
prior to definitive germlayer markers. From 2i ES cells and the Rex1GFP-positive 
fraction of serum ES cells this process follows similar kinetics. Therefore although 
serum induces transcriptional and epigenetic changes and associated metastability, 
developmental potential within the Rex1-positive compartment is not fundamentally 
altered. This is substantiated by the capacity of ES cells from either condition to con-
tribute extensively to chimaeras. However, a significant proportion of cells in serum 
lose expression of Rex1 and of core pluripotency factors such as Nanog and Klf4. 
They are developmentally more advanced and should be considered distinct from 
ES cells even though they retain Oct4 [45].
 Expression of many genes associated with metabolic and biosynthetic pro-
cesses is enriched in 2i. This is likely in large part a response to absence of se-
rum constituents, loss of MAPK signalling and inhibition of GSK3, and indicates 
that ES cells have adaptable metabolomic capacity. Probably as a consequence of 
low c-Myc, the cell cycle inhibitors p16, p19 and p21 are upregulated in 2i, even at 
the protein level (Figure S7D). Nonetheless, ES cells continue to proliferate rapidly, 
reflecting their freedom from cyclin checkpoint control [46, 47]. These features can 
explain the robust expansion of ES cells independent of serum factors and likely 
underlie their latent tumorigenicity [48].
 In 2i and serum H3K4me3 peaks are globally similar in number and intensity. 
In contrast, there is a striking difference in the pattern of H3K27me3 deposition. This 
mark is present as a lawn across intergenic regions and inactive genes (Figure 3C). 
However, elevated deposits at promoters of repressed genes are greatly diminished 
in 2i. The majority of these genes show reduced rather than increased transcription 
in 2i. This promoter-specific diminution in H3K27me3 is common to multiple ES cell 
lines. The majority of these genes show reduced rather than increased transcription 
in 2i. Ezh2 is localised less intensely at promoters in 2i, which may underlay the 
selective reduction in H3K27me3. Global levels of H3K27me3 are similar in 2i and 
serum. Indeed, H3K27me3 is increased at satellites in 2i, indicating that these may 
serve as a sink. Notably, there is no change in H3K9me3 over satellites (Figure 
S3C).
 In 2i only around 1000 genes have both H3K4me3 and H3K27me3 marks, 
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which argues against bivalency as a master epigenetic blueprint. Nonetheless, most 
of the remaining bivalent genes can be classified as developmental. In serum, more 
genes are bivalent due to acquisition of H3K27me3. Surprisingly, this is accompa-
nied by a slight overall increase in expression, although the majority remain silent 
or transcribed at very low level (Figure S6a). It is conceivable that although the local 
levels of PRC2 and H3K27me3 are reduced, they remain sufficient to repress tran-
scription. It should be noted, however, that ES cells lacking PRC2, PRC1 or both are 
viable and show de-repression of lineage-specific markers to only a low level [49]. 
Our findings are thus in line with genetic evidence that Polycomb is not a central 
mechanism for silencing gene expression in the naïve state and only becomes criti-
cal during differentiation.
 RNA polymerase pausing has been identified by GRO-seq analysis [50] at 
variable extents at many genes in ES cells cultured in serum. Our findings indicate 
that pausing is more prevalent in 2i than serum. Induction of c-Myc in serum may 
facilitate pause release at some loci. This is consistent with recent evidence that Myc 
function is unnecessary in naïve ES cells but required in serum [51]. However, many 
of the genes whose expression is most markedly upregulated in serum, including 
germ layer specification factors, are not reported Myc targets. Therefore additional 
mechanisms are likely to control pause release in ES cells.
 In mammals pluripotent cells harbour the germline and most pluripotency 
factors are also key players in germ cell specification and differentiation. It is inter-
esting therefore that in C.elegans and Drosophila, germline development is depen-
dent on transcriptional pausing mediated at the level of pTEFb antagonism by Pie-1 
and Pgc respectively [52]. This raises the question whether naïve ES cells might 
contain an analogous factor that interferes with pTEFb to suppress transcriptional 
elongation. It will also be revealing to determine whether Erk signalling may cause 
activation of pTEFb [53, 54].
 Recruitment and pausing of RNA polymerase II with lack of consolidated 
H3K27me3 silencing may constitute a potentiated template for induction of lin-
eage-specific transcription programmes. Pausing may serve to minimise the effects 
of noise and ensure rapid, coordinated and synchronous gene induction in response 
to developmental cues or extrinsic stimuli [55, 56]. Recent studies also indicate that 
Pol II pausing inhibits nucleosome assembly [57] and could thereby influence his-
tone modification profile. Interestingly, in Xenopus embryos H3K27me3 is not de-
posited during zygotic gene activation but is acquired later, associated with spatial 
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restriction of gene expression [58]. In the mouse ICM, H3K27me localisation has 
not been determined but various epigenetic silencing components appear to be ex-
pressed at low levels [25].
 Collectively the observations reported here yield new insights into the mo-
lecular underpinning of naïve pluripotency and revise previous assumptions derived 
from analysis of heterogeneous and metastable serum-treated cultures. The find-
ings provoke new questions about the regulation of gene expression in pluripotent 
cells and the process of lineage specification. Transcriptional potentiation through 
promoter proximal pausing may play a major role in the establishment and stable 
maintenance of naïve pluripotency. Currently there is great interest in isolating hu-
man pluripotent stem cells in a naïve state [3, 59]. The distinctive transcriptome and 
epigenome characteristics of ground state mouse ES cells may provide a valuable 
criterion against which to measure such claims. In addition, these datasets provide 
a benchmark resource for analysis and modelling of gene expression control during 
self-renewal and in the transition from naïve pluripotency to lineage commitment.
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EXPERIMENTAL PROCEDURES
Cell culture and methods
ES cells were cultured without feeders in the presence of leukaemia inhibitory fac-
tor (LIF) either in GMEM containing 10% foetal calf serum or in serum-free N2B27 
supplemented with MEK inhibitor PD0325901 (1μM) and GSK3 inhibitor CH99021 
(3μM), together known as 2i (Ying et al., 2008). E14Tg2a (E14), Rex1GFPd2 (RGD2, 
Rex1GFP), and HM1 are male ES cells of 129 background established and main-
tained in serum without feeders. The serum-derived female XT67E1 line is from a 
mixed 129 and PGK/C3H background [60]. TNGA female ES cells were derived and 
maintained in 2i from embryos on a mixed strain 129 and C57BL/6 background het-
erozygous for eGFP knock-in at the Nanog gene [6]. Female and male ES cells from 
the non-obese diabetic (NOD) strain were derived and maintained in 2i [21]. Chro-
matin immunoprecipitations (ChIP) were performed as described [61]. Cell sorting 
(FACS), immunoblotting, RNA isolation and cDNA synthesis were performed accord-
ing to standard protocols described in the extended experimental procedures, which 
also lists antibodies used.
Sequencing
DNA samples were prepared for sequencing by end repair of 20 ng DNA as mea-
sured by Qubit (Invitrogen). Adaptors were ligated to DNA fragments, followed by 
size selection (~300bp) and 14 cycles PCR amplification. Cluster generation and 
sequencing (36 bp) was performed using the Illumina Genome Analyzer IIx (GAIIx) 
platform according to standard Illumina protocols. The standard pipeline to generate 
the sequencing output files are described in the supplemental information. All se-
quencing analyses were conducted based on the Mus musculus NCBI m37 genome 
assembly (MM9; assembly July 2007). Table S1 summarizes the sequencing output. 
All RNA-seq and ChIP-seq data (FASTQ, BED and WIG files) are present in the 
NCBI GEO SuperSeries GSE23943.
RNA-seq analysis
To obtain RNA-Seq gene expression values (RPKM), we used Genomatix (www.
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genomatix.de). Differential genes were called at a two-fold difference and p<0.2 in 
a Student t-test (among three biological replicates for both 2i and serum). The iden-
tification of novel ncRNAs is described in the extended experimental procedures. 
GO and KEGG analysis was performed using DAVID (http://david.abcc.ncifcrf.gov/).
ChIP-seq analyses
To compensate for differences in sequencing depth and mapping efficiency, the total 
number of unique reads of each sample was uniformly equalized, allowing quantita-
tive comparisons. Tag densities on the average profiles were determined by calculat-
ing tag density over each bp (using a 40 bp window size) per 10 million total mapped 
reads. The genes used for the average epigenetic profiles were based on the 2000 
most active/ inactive genes in TNGA-2i. The 2000 lowest/ not expressed genes were 
selected by the additional requirement of H3K27me3 promoter enrichments of >3 
fold over background in either TNGA-2i or E14-serum. Random distribution values 
were determined by calculating average read densities of the genomic DNA profile 
(4.962 reads/kb at 10 million sequenced reads equivalent to an average density of 
1.489 per bp). Genes were considered bivalent if both H3K4me3 and H3K27me3 
were >3 fold over random distribution, similar to criteria applied by Mikkelsen et al. 
(2007). The RNA Polymerase II travelling was calculated as described by Rahl et al. 
(2010). The Chip-seq repeat analysis procedure is described in the supplemental 
information.
Differentiation assays
For monolayer neural differentiation we used Sox1-GFP (46C) ES cells, which con-
tain a GFP knock-in at the endogenous Sox1 locus [39]. Cells cultured in 2i or serum 
were plated at a density of 5000 cells per cm2. 16 hours after plating, media was 
switched to N2B27 to induce neural differentiation. Percentage of GFP-positive cells 
was determined by flow cytometry. For embryoid body (EB) differentiation, single 
EBs were formed by sorting 1500 cells into each well of PrimeSurface96U plates 
containing 15% serum and no LIF. Sixteen EBs were pooled each day and analyzed 
by RT-qPCR using TaqMan probes (Applied Biosystems).
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EXTENDED EXPERIMENTAL PROCEDURES
Double-stranded (ds) cDNA synthesis
Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s re-
commendations. 100µg total RNA was subjected to two rounds of poly(A) selection 
(Oligotex mRNA Mini Kit; Qiagen), followed by DNaseI treatment (Qiagen). 100-
200ng mRNA was fragmented by hydrolysis (5x fragmentation buffer: 200mM Tris 
acetate, pH8.2, 500mM potassium acetate and 150mM magnesium acetate) at 94°C 
for 90 seconds and purified (RNAeasy Minelute Kit; Qiagen). cDNA was synthesized 
using 5µg random hexamers by Superscript III Reverse Transcriptase (Invitrogen). 
Ds cDNA synthesis was performed in second strand buffer (Invitrogen) according to 
the manufacturer’s recommendations and purified (Minelute Reaction Cleanup Kit; 
Qiagen). Strand specific rRNA depleted ds cDNA profiling was performed using the 
ScriptSeq kit (cat. no. SS10924) from Illumina, according to the instructions of the 
manufacturer. rRNA depletion was performed using the Ribo-Zero rRNA Removal Kit 
(Human/Mouse/Rat; cat. no. RZH110424). Validation experiments were performed 
by RT-qPCR using primers as shown in Table S6.
Chromatin immunoprecipitation (ChIP)
Experiments were performed using 3.3x106 cells and 3µg antibody per ChIP as 
described (Marks et al., 2009) with two minor modifications. Crosslinking was perfor-
med on the culture plates for 20 minutes and ChIP’ed DNA was purified by Qiaquick 
PCR purification Kit (Qiagen). ChIP enrichment levels were analyzed by qPCR for 
quality control. Antibodies used for ChIP are described in the supplemental informa-
tion. Validation experiments were performed by qPCR using primers as shown in 
Table S6.
Antibodies used for ChIP
The following polyclonal antibodies were used for ChIP: H3K4me3 (Diagenode 
pAb-MEHAHS-024, A1-010); H3K27me3 (Millipore 07-449, DAM-1588246); H3K-
36me3 (Diagenode CS-058-100, A114-001); H3K9me3 (Abcam ab8898-100, lot 
733953) Ezh2 (Active Motif 39639, 23809001); RNA Polymerase II (Diagenode 
AC-055-100, 001; also known as the 8wg16 RNA Polymerase II antibody, with the 
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non-phosphorylated Ser2 of the RNA Polymerase II carboxyl-terminal domain (CTD) 
consensus sequence repeat YSPTSPS as main target. This antibody recognizes un-
phosphorylated (initiating) and Ser5 only phosphorylated RNA Polymerase II (Morris 
et al., 2005)).
Western blot analysis
For immunoblot analysis, 3µg of histone extracts (for histones; Abcam protocol) or 
10µg of nuclear extracts (for non-histone proteins; prepared according to Ambrosino 
et al., 2010) were resolved by SDS-PAGE and blotted on nitrocellulose membranes. 
Membranes were blocked for 1h in TBS-Tween containing 5% milk and incubated 
overnight at 4°C with the indicated antibodies diluted in TBS-Tween containing 3% 
milk. After washes, the membranes were incubated with secondary antibodies dilu-
ted in TBS-Tween containing 3% milk for 1h at room temperature. HRP conjugates 
were detected using enhanced chemiluminescence (ECL Plus, Amersham Bioscien-
ces). The following primary antibodies were used for Western: H3K4me3 (Diagenode 
pAb-MEHAHS-024, A1-010, 1:1000); H3K27me3 (Millipore 07-449, DAM-1588246, 
1:1000); H4 (Abcam, ab7311, 826236, 1:1000); Ezh2 (Active Motif 39639, 23809001, 
1:1000); Suz12 (Abcam ab12073-100, 418328, 1:500); β-actin (Abcam ab16039, 
104192, 1:500), p16 (M-156, sc-1207, H1810), p19_ARF (5-C3-1, sc-32748, A0411), 
p21 (F-5, sc-6246, G0210). Secondary antibodies used: HRP-conjugated polyclonal 
swine anti-rabbit IgG (Dako, P0399, 00042894, 1:4000); HRP-conjugated polyclonal 
rabbit anti-mouse IgG (Dako, P0161, 00046035, 1:3000); HRP-conjugated polyclo-
nal rabbit anti-rat IgG (Dako, P0450, 00017777, 1:1000).
Immunofluorescent stainings
Cells were fixed in 4% formaldehyde, permeabilized with 0.1% Triton X-100 and 
blocked using 3% donkey serum. Overnight incubation was performed with Oct3/4 
(Santa Cruz sc-5279, c-20), Klf4 (R&D Systems AF3158) or Nanog (E-biosciences 
14-5761-80) antibody at 4°C. Alexa Fluor 647 donkey anti-goat or anti-mouse IgG 
were used as secondary antibodies.
67
The transcriptome and epigenome of ground state pluripotency
Clonogenic assays
After sorting, ES cells were plated in serum or 2i + LIF at clonal density in duplicate 
wells (800 cells per well of a 6-well dish). Colonies were grown for 5 days in serum 
or for 7 days in 2i + LIF. Alkaline phosphatase staining was performed to score for 
colonies consisting of largely undifferentiated cells (undiff), mixed, and largely diffe-
rentiated (diff) cells.
Cell sorting (FACS)
Cell sorting was performed according to Wray et al. (2011).
Details of sequencing
Quality control of DNA libraries prepared for sequencing was made by qPCR and by 
running the products on a Bioanalyzer (BioRad). Samples were sequenced to a dep-
th of approximately 20 million uniquely mapped tags per sample. Sequences were 
aligned to the mouse MM9 reference genome using the Illumina Analysis Pipeline 
allowing one mismatch. Only the tags aligning to one position on the genome were 
considered for further analysis. For RNA-seq, further analysis was performed using 
the 36 bp aligned sequence reads. For ChIP-seq, identical sequence tags were di-
scarded to obtain a non-redundant set, and the 36 bp sequence reads were directio-
nally extended to 300 bp, corresponding to the length of the original fragments used 
for sequencing. The output data were converted to Browser Extensible Data (BED) 
files for downstream analysis and Wiggle (WIG) files for viewing.
Identification and quantification of known and novel ncRNAs
For de novo identification of ncRNAs of the strand specific RNA-seq, signals on the 
minus and plus strand were analyzed separately. Signals were quantified in 10 kb 
bins at a genome-wide scale. Bins that overlapped with known coding or non-coding 
RNAs (present in RefSeq, Genbank or ENSEMBL) were excluded for further analy-
sis. Subsequently, we selected bins with signals above background. Signals were 
averaged for TNGA 2i ES cells and E14 cells adapted to 2i (8 passages), as well 
as for E14 serum ES cells and TNGA cells adapted to serum (8 passages). Known 
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ncRNAs were selected from the RefSeq database. RNAs were considered to be 
differential if there was at least a twofold difference between the 2i and serum condi-
tions, with an extra constraint set by a p value < 0.2 (student t-test).
Peak calling
Identification of the H3K27me3 binding sites (peak calling) was performed using 
FindPeaks (Fejes et al., 2008) using a loose FDR cut-off of < 1 x 10-2, subpeaks 0.9, 
triangles distribution and duplicate filter. The number of tags per peak was normali-
zed for the genomic length of the peak (expressed as reads/kb), by which the pea-
ks were categorized (Figure 4A). Overlaps with genomic features were determined 
using Galaxy (main.g2.bx.psu.edu).
ChIP-seq repeat analysis
For the repeat analysis of ChIP-seq profiles, the mappings were performed using 
the maq (mapping and assembly with qualities) aligner version 0.7.1 (Li et al., 2008). 
The major advantage for the repeat analysis as compared to the ELAND Pipeline 
is that, if a sequenced read aligns on multiple places on the genome, maq assigns 
it randomly at one of these positions. This is useful when studying repeat classes, 
as the reads representing these classes will by definition map on multiple genomic 
locations. However, these will almost exclusively belong to the same class of re-
peat. All reads mapped by maq were included in downstream analyses. To enable 
direct comparisons, the samples were ratio normalized for the total number of tags 
mapped by maq. Sequence coordinates of various repeat classes were downloaded 
from the UCSC Table Browser (RepMask 3.2.7; rmskRM327). ChIP-seq tags were 
considered to represent a repeat class in case of any overlap of the 36 nt sequenced 
fragment with the repeat class. Subsequently, the number of ChIP-seq tags repre-
senting a repeat class was counted.
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Figure S1. Transcriptome profiling of ES cells in 2i and serum.
(A) Venn-diagram of genes specific for 2i (below detection limit in serum), present in both 2i and serum, 
or only present in serum (below detection limit in 2i). (B) Addition to Figure 1B: Expression of all Stem 
Cell Maintenance (SCM) genes, as annotated by Gene Ontology, with similar expression in 2i and serum. 
(C) RT-qPCR validation for all differential SCM genes shown in Figure 1B, and for Prdm1, Prdm14 and 
Nes (using two independent primer pairs, A and B respectively). (D) RNA expression of differential SCM 
genes, differential cell cycle control regulators and other key transcription factors in the Inner Cell Mass 
(ICM) versus serum (Tang et al., 2010; orange) and 2i vs serum (this study; blue). Shown is the fold chan-
ge (in log2 values as compared to serum ES cells.
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Figure S2. (previous page) Analysis of Rex1 positive and negative serum ES cell fractions.
(A) ES cell morphology in 2i or serum culture. (B) Oct4 (left) and Klf4 (right) immunostaining of ES cells 
in 2i or serum. Arrows point to Klf4 negative ES cells in serum. (C) GFP flow cytometry profile of the 
total population of Rex1-GFP serum ES cells (black) and ES cells without any GFP transgene (negative 
control, gray (largely overlapping red)). The GFP negative and positive sorted Rex1-GFP serum ES cells 
used in this study are shown in red and green, respectively. (D) Number of colonies after re-plating 2i ES 
cells and Rex1-positive and Rex1-negative ES cells at clonal density in serum (left) or 2i (right). After 5 
days (serum) or 7 days (2i + LIF), alkaline phosphatase staining was performed to discriminate between 
colonies consisting of largely undifferentiated cells (undiff), mixed, or largely differentiated (diff) cells. (E) 
Klf4 and Nanog immunostaining of unsorted Rex1-GFP serum ES cells. The arrowheads in the DAPI 
stainings point to Rex1, Klf4 and Nanog negative cells, the arrows in the GFP+Klf4+Nanog stainings 
to Rex1-positive, but Klf4 and Nanog negative cells. (F) Comparison of expression of pluripotency and 
lineage-specific genes (as shown in Figures 1B and 1D) of Rex1 positive (Serum-Rex-pos) and Rex1 ne-
gative (Serum-Rex-neg) ES cells. (G) Transcript levels of genes associated with the various germlayers 
in Rex1-positive and Rex1-negative serum ES cells. (H) Functional analysis of the differential genes 
between Rex1-positive and Rex1-negative serum ES cells. (I) Functional analysis of the differential genes 
between 2i ES cells and Rex1-positive serum ES cells.
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Figure S3. H3K27me3 is greatly diminished at promoters of silent genes and at Hox clusters in 
ES cells in 2i.
(A) Expression levels of the two groups of genes shown in Figure 3A. For comparative purposes, the 
expression level of all genes equally divided into ten bins according to expression level is shown at the 
bottom. (B) Similar to Figures 3A and 3B: Average H3K9me3 profiles over active and inactive genes, as 
well as the negative control (genomic DNA derived from the chromatin input) (C) Percentage of H3K9me3 
tags present in the major repeat categories. (D) Quantification of the H3K9me3 enriched genomic loci, as 
determined by Yuan et al. (2009), in 2i and serum. (E) Typical examples of H3K9me3, enrichment over 
three imprinted genes. (F) H3K27me3 (“K27”) and H3K36me3 (“K36”) intensity plots for the genomic 
coding regions of all genes (ranked by TNGA-2i H3K36me3 values), showing that H3K27me3 and H3K-
36me3 are mutual exclusive. (G) Similar to Figure 3B: H3K27me3 profiling of biological replica of TNGA in 
2i. (H) Expression of the genes shown in panel Figure 3F. See Figure S3A (bottom) for a binned overview 
for the expression level of all genes. (I) Validation of the ChIP-seq and RNA-seq profiles by ChIP-qPCR 
or RT-qPCR, respectively.
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Figure S5 related to Fig 4 
Figure S4. (previous page) Interconvertibility of the epigenome between ES cells in 2i and serum.
(A) Typical examples of the interconvertibility of the H3K27me3 and Ezh2 epigenome in 2i and serum ES 
cells. (B) Average H3K4me3, H3K36me3, H3K27me3. H3K9me3, Ezh2 and Suz12 epigenetic profiles at 
2000 most active (left plots) and 2000 silent (right plots) genes around the 5’ and 3’ end, in TNGA cells 
(left; TNGA 2i: maintained and derived in 2i; TNGA serum; adapted to serum) and E14 cells (right; E14 
serum: maintained and derived in serum; E14 2i: adapted to 2i). (C) UCSC genome browser examples of 
known and novel ncRNA, identified and quantified using strand specific rRNA depleted RNA-seq. RNA-
seq signals on the + strand have positive values (dark pink), signals on the - strand have negative values 
(light pink). Differential expression of these genes is clearly supported by the H3K4me3 and H3K36me3 
epigenome profiles.
Figure S5. H3K27me3 deposition.
(A) Expression levels of PRC2 and PRC1 subunits, and H3K27me3 demethylases, as determined by 
RNA-seq. (B-C) Western blot analysis of PRC2 subunits (B) and pThr345-Ezh2 (C).
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Figure S6. Bivalency.
(A) Expression levels and H3K4me3/ H3K27me3 levels of genes bivalent in 2i, serum or both. (B-C) Bi-
valent marks are interconvertible between 2i and serum conditions. H3K27me3 and H3K4me3 intensity 
plots at the promoters of all genes similar to Figure 5A, but including the E14 cells (B). H3K27me3 and 
H3K4me3 intensity plots of all promoters that are bivalent in TNGA serum using a similar setup as Figure 
5C, but including the E14 cells (C).
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Figure S7 related to Fig 5 
Figure S7. RNA polymerase II pausing in naïve ES cells.
(A) Addition to Figure 6A: Averaged RNA Polymerase II, H3K4me3, H3K36me3 and H3K27me3 profiles 
at promoters of Myc target genes upregulated in serum. (B) Gene expression as determined by RNA-seq 
of genes involved in the typical G1/S checkpoint network (after Burdon et al. (2002)). (C) Gene expression 
of the major cell cycle regulators with differential gene expression between cells grown in 2i and serum. 
Left: Genes higher in serum; Right: Genes higher in 2i. The expression values of Rex1-positive serum 
ES cells are also included. (D) Western blot analysis for p16 (INK4a), p19 (ARF) and p21. (E) Averaged 
H3K4me3, H3K36me3 and H3K27me3 profiles of the promoter region of genes that are more highly 
expressed in 2i (left) or serum (right). Profiles for TNGA 2i ES cells and E14 2i adapted ES cells are com-
bined to generate average values and error bars (2i), the same was performed for E14 serum ES cells 
and the TNGA serum adapted ES cells (serum). (F) RNA-seq expression levels of regulators of pausing 
and pause release (TefB, NELF, DSIF, PAF) in 2i and serum. 
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ABSTRACT
DNA methylation is a long known epigenetic mark involved in many biological 
processes and the ‘readers’ of this mark belong to several distinct protein families 
that ‘read’ and ‘translate’ the methylation mark into a function. Methyl-CpG binding 
domain proteins belong to one of these families that are associated with transcriptional 
activation/repression, regulation of chromatin structure, pluripotency, development 
and differentiation. Discovered decades ago, the systematic determination of the 
genomic binding sites of these readers and their epigenome make-up at a genome-
wide level revealed the tip of the functional iceberg. This review focuses on two 
members of the methyl binding proteins, namely MBD2 and MBD3 that reside in very 
similar complexes, yet  appear to have very different biological roles. We provide a 
comprehensive comparison of their genome-wide binding features and emerging 
roles in gene regulation.
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INTRODUCTION
DNA methylation
 
 DNA methylation of cytosine residues was reported to be involved in gene 
silencing as early as 1975 [1, 2] and represents the first epigenetic mark [2]. In 
mammals, the predominant form is cytosine methylation (5mC) found within the 
context of paired symmetrical methylation at CpG dinucleotides. In mammalian 
genomes, around 70% of CpG dinucleotides are methylated [3], however, CpG 
islands (CGIs) - regions of local high CpG density - are mainly unmethylated. CGIs 
constitute around 60% of human promoters [4]. Methylation of CGI promoters 
results in transcriptional silencing, for example during genomic imprinting and 
X-chromosome inactivation [5-7]. For many years, DNA methylation has been 
regarded as long lasting and an epigenetic lock on transcription. Cases of highly 
dynamic regulation of DNA methylation were reported by the Gannon and Reid 
laboratories [8, 9], suggesting cyclical methylation/demethylation at promoters 
as a part of the transcription cycle at least at some promoters. They showed that 
the process involves DNA methyltransferases (DNMTs) as well as thymine-DNA-
glycosylase (Tdg). The recently discovered active DNA-demethylation pathway 
involves Ten-eleven translocation (Tet) enzymes [10-12]. Tet enzymes catalyze 
conversion of 5mC to 5-hydroxymethylcytosine (5hmC) and can further oxidize 
5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Tdg can excise 
the latter two derivatives through base-excision-repair process that will generate 
un-methylathed cytosines [12-14] closing the methylation cycle. The breakthrough 
discovery that Tet enzymes can oxidize 5-methylcytosine has revolutionized the 
concepts in the epigenetic field in general and the DNA methylation field in particular.
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DNA-methylation and its readers
 The relationship between DNA methylation and transcriptional silencing has 
proven challenging to decipher. Essentially, two types of mechanisms have been put 
forward: in the first a methylated cytosine physically inhibits binding of transcriptional 
regulators. It was reported that the binding of transcription factors such as AP-2 [15], 
c-Myc [16], NF-kB [17], E2F1 [18] and CREB [19], is affected by DNA methylation. 
 The prevalent model proposes that proteins bind directly to methylated 
DNA– the so-called readers –, recruit co-repressor complexes [20] and trigger the 
formation of repressive chromatin. Methylated DNA readers fall into three main 
classes: i) proteins containing a methyl-CpG-binding domain (MBD), ii) Kaiso and 
Kaiso-like family of proteins including ZBTB4-33-38, characterized by the presence 
of BTB/POZ domain and several Kruppel-like C2H2 zinc fingers and iii) SRA (SET 
and RING finger associated) domain containing proteins, like UHRF1 and UHRF2 
characterized by the SRA domain that recognizes methylated DNA. Recently, a DNA 
pull-down screen followed by Mass Spectrometry has uncovered additional 5mC 
and 5hmC readers that do not belong to any of the three families listed above [21], 
such as some homeobox and Rfx proteins.
The MBD family of proteins
 
 The founding member of the MBD family is MeCP2 [22], a protein of 53kDa 
containing an N-terminal MBD [22, 23] and a C-terminal transcription repression 
domain (TRD) [24]. MeCP2 is ubiquitously expressed and highly abundant in the 
brain. Mutations in the gene encoding MeCP2 cause the Rett syndrome [25] and 
other neurodevelopmental disorders [26]. Crystal structure of the MBD domain, in 
complex with methylated DNA, showed that it binds symmetrical methylated CpGs 
in vitro. The MBD domain of MeCP2 - a domain of 70 amino acids - has been used 
in homology searches that led to the identification of six additional family members 
named MBD1 to MBD6 (Figure 1)[27]. Other studies revealed four additional proteins 
that contain an MBD-like domain namely SETDB1, SETDB2 [28], BAZ2A and BAZ2B 
[29].
 MBD1, MBD2 and MBD4 can bind methylated DNA in vitro, while MBD3, 
MBD5 and MBD6 do not appear to bind methylated DNA, at least not in vitro [30].  A 
recent study on MBD5 and MBD6 revealed that their MBD domains interact with the 
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human PR-DUB complex [31]. MBD1, MBD2, MeCP2 and Kaiso appear not to be 
essential for development since their deletion is not embryonic lethal whereas MBD3 
plays an essential role in embryonic development [32, 33].
 MBD2 and MBD3 are close relatives and probably descend via gene 
duplication from an ancestral MBD2/MBD3, that is present in some metazoans as 
for instance Caenorhabditis elegans and Drosophila [34]. Outside the MBD domain, 
MBD2 and MBD3 share almost 80% homology; they both have an MBD and a coiled-
coil domain. Apart from this common domain, MBD2 contains an additional N-terminal 
glycine-arginine (GR) rich domain and a transcriptional repressor domain (TRD), 
whereas MBD3 has a C-terminal poly-glutamate region. Three isoforms have been 
described for MBD2 protein: the full length MBD2a, MBD2b lacking the N-terminal 
GR repeat and MBD2c that is a testis specific isoform lacking the C-terminus. Also 
MBD3 presents three isoforms: Mbd3b - the major isoform in embryonic stem cells, 
Mbd3a and a smaller isoform Mbd3c [35]. The crucial difference between MBD2 and 
MBD3 is that MBD3 does not bind methylated DNA, because it lacks four conserved 
aminoacids in the MBD domain. 
 
MBD TRD
CxxC
1 2 3
MBD TRD
CCMBDTRDGR
CCMBD
MBD GLY
MBD
MBD
PWWP
MeCP2
MBD1
MBD2
MBD3
MBD4
MBD5
MBD6
Figure 1 Figure1 The MBD family of proteins 
Schematic overview of the mammalian 
MBD family and their known domains 
(MBD, methyl-CpG-binding domain; 
TRD, transcriptional repression do-
main; CXXC, Zinc finger-Cys-x-x-Cys 
domain; G/R, arginine-rich; CC, coi-
led-coil; GLY, glycosilase; PWWP, Pro-
Trp-Trp-Pro).
Figure 1
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MBD protein complexes: looking for functions
 Biochemical data provided strong evidence that methyl-CpG-binding 
domain proteins (MBPs) are an integral part of chromatin-remodeling complexes 
reported to mediate heterochromatin formation and transcriptional silencing.  MeCP2 
transiently interacts with the Sin3A and HDAC2 complexes [24], and MBD1 with 
SETDB1, SUV39H and HP1 [36, 37]. MBD2 and MBD3 are integral parts of the Mi-2/
NuRD complex [38, 39]. Mi-2/NuRD complex is containing ATP-driven chromatin 
remodeling and histone deacetylase activities. Protein interaction studies have 
demonstrated that MBD2 and MBD3 bind HDAC1/2 [38, 40], GATAD2A (p66 α) and 
GATAD2B (p66 β) [41-43]. Initially MBD2 and MBD3 were thought to be part of the 
same complex. It was postulated that Mi-2/NuRD containing both MBD2 and MBD3 
is recruited to methylated DNA via MBD2 [38]. Knockout studies however showed 
that MBD2 and MBD3 have distinct functions because MBD3, but not MBD2, is 
embryonic lethal [44]. Indeed biochemical analyses showed that MBD3 and MBD2 
are mutually exclusive within the Mi-2/NuRD complex [39]. In addition to the already 
known Mi-2/NuRD components, DOC-1 was identified as a novel subunit of both 
MBD2-NuRD [39, 45] and MBD3-NuRD [21]. 
MBD proteins in transcription regulation
 The role of MBPs in transcription regulation has been widely studied. 
MBPs have often been associated with transcriptional repression because of their 
interaction with co-repressor complexes triggering heterochromatin formation. 
However, a unifying role and mechanism have yet to be established. Informative 
approaches to decipher the function of a protein are knock-down (KD), knock-out (KO) 
and overexpression studies. Surprisingly, knock-down as well as overexpression of 
MeCP2 have been reported to cause both transcription activation and repression 
in the hypothalamus, with 85% of target genes being activated by MeCP2 [46]. 
Also the KD of MBD2 resulted in both transcriptional activation and repression. For 
instance it has been shown that in adult erythrocytes, MBD2 and MTA2 – a Mi-2/
NuRD subunit -- are enriched at the inactive ρ-globin gene when this gene is highly 
DNA methylated and repressed. MBD2 KD resulted in re-expression of the ρ-globin 
gene [47]. Another direct target of MBD2-mediated repression is the Il4 gene, whose 
level of expression is increased in T cells derived from Mbd2-null mice [48].  MBD2 
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was also reported to affect the Xist gene silencing in mouse: Mbd2 knock-down 
cells display lower level reactivation of Xist whereas silencing was rescued by re-
expression of Mbd2 [49]. 
 In a recent study, the link between MBD2 binding and expression changes 
of neighboring genes was assessed using chromatin immunoprecipitation (ChIP) 
experiments following MBD2 depletion [50]. Only mild alterations in gene expression 
were observed. Moreover, after MBD2 depletion, gene expression changes revealed 
a roughly equal number of genes that were up or down-regulated. As mentioned 
above, the level of DNA methylation nor imprinting are affected in MBD2 null mice 
suggesting that it is not required for correct silencing of imprinted genes.
 Taken together, the generally accepted model of MBD2 acting as a 
transcriptional repressor has not been unambiguously supported by experimental 
data and a unifying model of the molecular mechanism is missing.
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MBD2 and MBD3: the complex balance of pluripotency/reprogramming
 
 MBD2 has two isoforms: the full length MBD2a and a testis specific isoform 
MBD2c, lacking the C-term [27]. The C-term domain of MBD2 is responsible for the 
interaction with p66α (GATAD2A) and therefore with the Mi2-NuRD complex [41, 
42]. Protein interaction studies have shown that MBD2c is unable to bind Mi-2/NuRD 
components such as Mi-2β, HDAC1 and HDAC2[51]. A recent study showed that in 
human pluripotent stem cells the two isoforms sustain different pathways: MBD2a 
promotes differentiation and its overexpression disrupts pluripotency while MBD2c 
facilitates reprogramming of fibroblasts [52]. Moreover this study shows that the 3′ 
UTR of MBD2a is a direct target of the miR-302, previously reported to promote 
reprogramming [53] via up-regulation of NANOG expression and suppression of 
MBD2 [54]. These recent findings shed new light on the role of MBD2 in regulating the 
commitment towards either reprogramming or differentiation, involving the microRNA 
and splicing factors. Further analysis will be needed to dissect the transcriptional 
and epigenetic changes in response to deletion of either isoforms, in order to identify 
specific targets and downstream effectors that might be mediating either lineage 
commitment or retention of pluripotency. 
 The role of MBD3 in lineage commitment and pluripotency has recently been 
at the focus of attention [55-57].  The importance of MBD3 in regulating escape from 
pluripotency and lineage commitment has been documented in several studies. Early 
reports described Mbd3 as essential for lineage commitment, since Mbd3 depleted 
mouse embryonic stem cell failed to differentiate and aberrantly self-renewed 
independently of LIF (leukemia inhibitory factor), one of the essential factors needed 
to keep undifferentiated stem cells in culture [35]. Recently two independent studies 
showed that Mbd3 constitutes a gate to full reprogramming and that its depletion 
together with transduction of the four Yamanaka factors (Oct4, Sox2, Klf4, Myc, all 
together OSKM) enhances the reprogramming efficiency, consistent with the role of 
Mbd3 as suppressor of reprogramming [58, 59]. However, other findings suggest 
an opposite role for Mbd3 in facilitating induction of pluripotency [60]. The authors 
themselves underline that the differences with respect to previous studies might be 
due to a different cell system and reprogramming conditions, and that their findings 
may be context specific. However reproducibility of previous results seemed to be 
somewhat challenging, raising more questions than providing answers.  
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MBPs in the organization of chromatin structure
 Several studies have pointed to a role of MBD proteins in the organization 
of chromatin structure and shaping the local and global epigenome landscape, for 
instance formation or maintenance of heterochromatic, repressive chromatin [61, 
62], given the presence of an ATP-driven remodeler subunit within the Mi-2/NuRD 
complex. [38, 40]. 
 Little is known about the impact of MBD2 on chromatin organization in vivo. 
It has been observed that mouse myoblasts undergoing myogenic differentiation 
form aggregates of pericentric heterochromatin (chromatin surrounding the 
centromers) that display increased levels of MeCP2, MBD2 and DNA methylation 
[63, 64]. Overexpression of MBD2 or for that matter MeCP2 induced condensation 
of densely stained heterochromatin within the nucleus. Interestingly also in the 
absence of MeCP2 (skeletal muscle tissue derived from MeCP2 knock-out mice), 
MBD2 overexpression triggered the formation of densely stained repressive 
chromatin, suggesting some degree of functional redundancy or overlap. The 
molecular mechanisms behind this aggregation of pericentric chromatin remain 
unclear. A recent study shows that in human cells ectopic expression of MBD2, but 
not MBD3, induces heterochromatin compaction [50]. To resolve the putative role 
of MBD2 in the formation of higher order chromatin structure it will be important to 
combine genome wide localization studies with chromosome conformation capture 
approaches. A first study along these lines [65] indeed suggests  that MBD3 binding 
to enhancers results in their closer proximity to promoters and gene bodies because 
of protein mediated looping. 
Genome wide MBD2 and MBD3 binding site analyses
 
 Chromatin immunoprecipitation followed by next generation sequencing, 
(ChIP-seq) is widely used to determine the binding sites of a protein or transcription 
factor in a genome wide manner. A substantial amount of literature describes 
the characterization of MBD2 and MBD3 binding to chromatin at specific loci but 
only recent studies provided genome wide maps. ChIP experiments on chromatin 
regulators, such as Mi-2/NuRD complex, turned out to be quite challenging, 
presumably because of a combination of factors: low abundancy of the proteins, the 
transient nature of the chromatin association, short residence time on chromatin and 
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the quality of the antibodies. 
 Recent genome-wide mapping of MBPs has clearly shown that MBD2 binds 
to highly methylated, CpG dense regions in vivo [51]. Interestingly, motif analysis did 
not reveal any specific DNA sequence motif within the MBD2 binding sites and their 
flanking regions, but highlighted primarily CG richness of the binding sites as the 
critical factor for binding. In line with this, an intact methyl binding domain is essential 
to target MBD2 to densely methylated loci. DNA methylation is a prerequisite since 
binding of MBD2 is lost in cells with triple knock-out for Dnmt1-3a/b, that lack both 
methylation and hydroxymethylation. MBD2 primarly binds at highly methylated 
promoters [50, 66] and secondly exons (Figure 2A-B). Surprisingly, in mouse 
embryonic stem cells, a correlation between genome wide MBD2 binding and 
known components of the Mi-2/NuRD complex such as Mi-2β and Hdac2 was not 
observed. It should be noted however that the profiles for the two subunits were not 
performed in parallel [56].  Interestingly, a subset of MBD2 binding sites have been 
uncovered that did not have DNA methylation. The presence of MBD2 at these loci 
was suggested to be due to its association with the Mi-2/NuRD complex that was 
recruited to chromatin via other, not yet identified factors (Figure 2C). Indeed, MBD2 
binding at such loci was lost when the testis specific MBD2 isoform was expressed 
that lacks the C-terminus and does not immunoprecipitate any of the known Mi-2/
NuRD components. Surprisingly, Baubec et al. also found that MBD2 is recruited 
to a subset of un-methylated loci that displayed epigenetic marks pointing at active 
regulatory regions. These data were confirmed in another independent study in 
which a tagged MBD2 was expressed in human MCF-7 cells. A small fraction of 
MBD2 binding sites was observed at promoters of genes displaying active histone 
marks and low gene expression [66]. Interestingly, the study from Gunther et al., 
revealed a dichotomy within MBD2 binding to promoters of silent genes and at the 
same time to exons of actively transcribed genes, suggesting that in the latter case, 
MBD2 might play a role in splicing. It remains to be elucidated what the effects of 
MBD2 binding are on transcription and chromatin organization. 
 Identification of genome-wide binding sites and functional analyses of 
MBD3 have been performed in mouse [51, 57] and human cells [50, 65] reaching 
different conclusions. Yildirim and coworkers reported that MBD3 binds just 
downstream of the transcription start site (TSS) of CpG-rich promoters marked by 
hydroxymethylation. Schubeler and coworkers found, however, that MBD3 binds to 
active regulatory regions (enhancers) independent of CpG density and independent 
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of their methylation or hydroxymethylation status, since binding was maintained in 
Dnmt1/3a/3b triple knock-out embryonic stem cells. These data question the validity 
of the binding of MBD3 to hydroxymethylated DNA, which was further underpinned by 
DNA pull-downs followed by MS analysis [21], which did reveal hydroxymethylation 
specific readers but in which MBD3 was not detected. 
 Independent studies in human cells [50, 65] both suggested that MBD3 is 
localized at CpG rich promoters of active genes, but while Gunther et al showed 
that it mainly binds promoters, Shimbo and coworkers suggested a more complex 
regulation of both active and silent genes. They showed that a fraction of MBD3 binds 
at enhancers that are in physical proximity to promoters and gene bodies in three-
dimensional space and hence are picked up in the assay. Since these data have 
been generated by different groups, using different antibodies, cell systems, and 
sequencing analysis pipelines (see Table1 for a summary of the different studies), 
re-analysis of the data with a common approach may resolve some of the major and 
minor discrepancies. Interestingly, the genome wide binding map of MBD3 correlates 
to some extend with that of another Mi-2/NuRD component, Mi-2β, implying partial 
co-recruitment of these two subunits on chromatin. Further studies will be needed 
to assess whether this interaction is necessary for Mi-2/NuRD to bind the chromatin 
and whether MBD3 depletion would result in loss of Mi-2β binding or vice versa. 
Similar as reported for MBD2, depletion of MBD3 in human [50] and mouse cells 
[57] resulted in alteration of gene expression for only a small number of genes and 
in both cases, the transcriptional changes are rather mild. 
 Taken together, the above findings suggest that MBD3 binds CpG-rich active 
promoters and enhancers that are not DNA methylated (Figure 3). The downstream 
functional consequence of MBD3 binding has still to be elucidated. 
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Figure 2 MBD2 binding to chromatin 
(A) Schematic representation of MBD2 
binding to highly methylated CGI pro-
moters (B) MBD2 binding to highly 
methylated CGI exons. (C) Subset of 
MBD2 binds to un-methylated active 
promoters, this binding depends on the 
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Figure 3 MBD3 binding to chromatin 
(A) Schematic representation of MBD3 
binding to unmethylated CGI promo-
ters (B) MBD3 binding to unmethylated 
enhancers, that are in physical proxi-
mity to promoters in three-dimensional 
space. The question mark indicates the 
possible presence of other subunits in-
volved in this association. 
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Table1.  Summary of studies characterizing MBD3 binding genome wide: Technical 
details of the experiments together with findings and algorithm used for the analysis 
are listed. 
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CONCLUDING REMARKS
 
 Since its discovery in 1975, DNA methylation has been one of the best studied 
epigenetic marks and the readers of DNA methylation that translate the signal of methylated 
DNA into a function or activity have obtained a lot of attention. MBD2 and MBD3 are two 
very similar proteins, which are interchangeable structural parts of the Mi-2/NuRD complex 
and share many common subunits. Nevertheless, they appear to perform distinct functions 
and to differ completely in their ability to bind methylated DNA. The emerging picture is 
that MBD2 binds to CpG-rich, densely methylated DNA in vivo, with an apparent but not 
understood preference for promoter regions. A minor fraction of MBD2 is present at promoters 
that bear active epigenetic marks and are not methylated. This is the only fraction of binding 
sites depending on the interaction with Mi-2/NuRD, suggesting that MBD2 might also have 
a function independent of Mi-2/NuRD.  Recruitment of Mi-2/NuRD might also depend on 
subunits other than MBD2 such as GATAD2A-B or MTA1-2 that is reported to directly bind 
the histone H3 tail in vitro [3, 67]. Supporting in vivo data is currently not available. Therefore 
additional biochemical studies followed by in vivo evidence, for example by ChIP-seq, 
should be performed to assess whether MBD2 exists in distinct complexes and can bind 
to unmethylated regions independent of Mi-2/NuRD. MBD3 binds CpG-rich, unmethylated 
active promoters and enhancers. One of the burning questions is how MBD3/NuRD is 
recruited to its genomic binding sites. Does MBD3 play a role, are other subunits important or 
is the association based on transient protein-mediated interactions? What seems clear is that 
MBD3 plays an important role in lineage commitment. 
 The biological functions of MBD2 and MBD3 remain an open question; whether and 
how they modulate transcriptional activity and chromatin structure. The recent coupling of 
chromosome conformation capture technologies with deep-sequencing might provide an 
interesting angle to look for possible participation of MBD2 in long range interactions, a model 
proposed for MBD3 but not yet addressed in a genome-wide fashion. Even after decades of 
research, DNA methylation readers are still hiding their true nature, raising puzzling but at the 
same time intriguing questions for further research.  
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ABSTRACT
MBD2 is a subunit of the NuRD complex that is postulated to mediate gene repression 
via recruitment of the complex to methylated DNA. In this study we adopted an MBD2 
tagging-approach to study its genome wide binding characteristics. We show that in 
vivo MBD2 is mainly recruited to CpG island promoters that are highly methylated. 
Interestingly, MBD2 binds around 1 kb downstream of the transcription start site of 
a subset of ~400 CpG island promoters that are characterized by the presence of 
active histone marks, RNA polymerase II (Pol2) and low to medium gene expression 
levels and H3K36me3 deposition. These tagged-MBD2 binding sites in MCF-7 show 
increased methylation in a cohort of primary breast cancers but not in normal breast 
samples, suggesting a putative role for MBD2 in breast cancer. 
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INTRODUCTION
 DNA methylation is the covalent addition of a methyl group to the cytosine 
of a CpG dinucleotide and represents an important epigenetic mechanism involved 
in several biological processes like X-inactivation [1], differentiation [2], genomic 
imprinting [3] and cancer [4].
 Around 70% of the CpG dinucleotides (CpGs) in the mammalian genome are 
methylated [5] except for CpG islands (CGIs), regions of high CpG density, that are 
usually unmethylated [6]. However, CGIs promoters are not always unmethylated and 
can acquire methylation during differentiation [7] or they can be aberrantly methylated 
in cancer [8]. Methylation of promoter CpG-islands is correlated to transcriptional 
repression [9] whereas recent evidences show genome-body methylation being 
mainly associated with transcriptional activity [10,11] [12].
 It has been proposed that one of the mechanisms of transcriptional repression 
mediated by CpGs methylation involves binding of methyl-CpG-binding proteins 
(MBPs) to the methylated cytosine and recruitment of a co-repressor complex [13]. 
MBPs are divided in three different families: MBD (methyl binding domain), Kaiso 
and SRA domain proteins [14]. The MBD family includes MeCP2, MBD1, MBD2 and 
MBD4 that can bind methylated DNA via the Methyl-CpG Binding Domain (MBD) 
while three other members of this family namely MBD3, MBD5 and MBD6 do not 
bind methylated DNA [15]. 
MBD2 is a subunit of the Mi2-NuRD complex that was previously shown to mediate 
gene repression via recruitment of the complex to methylated promoters [16,17]. 
Since promoter hyper-methylation is a well-known hallmark of cancer, several studies 
linked MBD2 function to epigenetic regulation of genes critical during carcinogenesis 
[18,19], however, most of these studies looked at a limited number of target genes. 
Recent studies challenged the model of MBD2 as a predominantly promoter-proximal 
repressor suggesting that binding could also regulate activity of target genes [20].
 Although it has been widely shown that MBD2 selectively binds methylated 
DNA in vitro [21,22] the proof that this also occurs in vivo was only recently provided 
by genome wide binding of MBD2 and other family members by comprehensive 
chromatin immunoprecipitation (ChIP) sequencing [23,24].  Genome wide mapping 
of MBD2 binding in mouse embryonic stem cells showed that in vivo binding 
predominantly occurs at highly methylated, CpG dense regions, although a subset 
of binding sites was detected at active unmethylated promoters. Another recent 
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study in HeLa cells showed that MBD2 mainly binds promoters of inactive genes and 
extrapolated this observation to imply that MBD2 acts as repressor at those regions 
[23].
 To gain further insights into the function of and epigenetic regulation by 
MBD2 we generated a tagged version of the protein and stably expressed it in the 
MCF-7 cell line. We mapped genome wide binding of MBD2 by ChIP sequencing 
(ChIP-seq) and together with base resolution whole genome bisulfite sequencing 
(WGBS) we determined the methylation content and the possible role of methylation 
density at MBD2 enriched regions. We also categorized the epigenetic make up of 
MBD2 binding sites taking advantage of a large body of ChIP-seq data and detected 
MBD2 at a subset of lowly active promoters. Regions bound by MBD2 in MCF-7 
show overall increased methylation levels in a large set of primary breast cancer 
samples but not in a model of non-cancer human mammary epithelial cells. 
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RESULTS AND DISCUSSION
Tagged MBD2 incorporates into native NuRD-complex
 In order to study the genome wide binding of MBD2 we generated a tagged 
version (hereafter referred as TTE-MBD2, Fig 1A) stably expressed in MCF-7 as at the 
initiation of this study, the available commercial MBD2 antibodies were of low quality 
and/or not suited for ChIP-seq. The epitope tag (TY1-TY1-ER) had already been 
successfully used for IP and ChIP applications [25] and was placed at the N-terminus 
of the protein. TTE-MBD2 expressed in MCF-7 cells is specifically recognized by 
the Ty1 antibody (Fig1B left panel), that does not detect the endogenous protein in 
wild type MCF-7 cells (WT). Western blot analysis with an MBD2-specific antibody 
showed that the tagged protein is expressed considerably higher as compared to 
endogenous MBD2 levels (Fig 1B, right panel).
 Next we performed large-scale Ty1 immunoprecipitation on both TTE-
MBD2 and WT cells followed by mass spectrometry analysis in order to determine 
whether the exogenous TTE-MBD2 is assembled into a NuRD complex. Results 
from triplicate pull-downs were analyzed with MaxQuant and label-free quantitation 
(LFQ) intensities were used to determine statistically enriched MBD2 interactors as 
previously described [26]. Amongst the 25 most significantly enriched interactors, the 
well-known MBD2-NuRD complex components CHD3/4, GATAD2A/B, MTA1/2/3, 
HDAC1/2 and CDK2AP1 (DOC-1) are co-precipitated (Fig1 C, black squares). We 
further detected RBBP4 but not RBAP46 (RBBP7) which share 90% sequence 
homology. A list with the specific interactors is reported (Table1) and a full list of 
all identified proteins is also available (Table S1). Interestingly, among the specific 
interactors we could detect several zinc-finger and other DNA binding proteins. Our 
findings indicate that the tagged MBD2 is at least in part incorporated in a NuRD-
like complex [21] and thus that the tag unlikely interferes with the composition of the 
complex. 
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Figure 1
Figure 1 Generation of a tagged MBD2. 
(A). Schematic presentation of tagging approach: double Ty1 and ER epitopes are inserted at the N-ter-
minal of human full length MBD2. (B). Western blot on whole cell lysates from TTE-MBD2 MCF-7 and 
WT MCF-7. Antibodies against tag (Ty1) and MBD2 are used. GAPDH is shown as loading control. (C). 
Volcano plot showing results from Mass Spectrometric Analysis of immunoprecipitation experiment. The 
x-axis shows the log of ratios between LFQ intensities in TTE-MBD2 against the control WT. The y-axis 
display −log10 of the p-value calculated by a permutation-based FDR-corrected t test. The black dots 
underline Mi2-NuRD complex components within the significantly enriched interactors (grey dots).
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Table1 List of TTE-MBD2 specific interactors identified from Mass 
Spectrometry
Gene 
names
Protein names (-)Log t-test p 
value
t-test Differ-
ence
MTA1 Metastasis-associated 
protein MTA1
8.32954 1.84248
ZNF512B Zinc finger protein 
512B
8.03327 1.34558
CHD4 Chromodomain-he-
licase-DNA-binding 
protein 4
7.75574 2.20372
BCL11B B-cell lymphoma/leu-
kemia 11B
7.58416 2.79627
CTBP2 C-terminal-binding 
protein 2
7.27166 2.11806
HDAC2 Histone deacetylase 
2;Histone deacetylase
6.60528 2.09939
CUX1 Homeobox protein cut-
like 1
6.17975 2.21916
GATAD2A Transcriptional repres-
sor p66-alpha
6.14678 2.2355
MTA3 Metastasis-associated 
protein MTA3
6.1107 2.4135
TRPS1 Zinc finger transcrip-
tion factor Trps1
6.04 3.19905
ZBTB7B Zinc finger and BTB 
domain-containing 
protein 7B
6.03263 3.31228
CDK2AP1 Cyclin-dependent 
kinase 2-associated 
protein 1
5.69484 2.27067
HDAC1 Histone deacetylase 1 5.64503 2.09078
ZNF219 Zinc finger protein 219 5.42088 2.24232
CHD3 Chromodomain-he-
licase-DNA-binding 
protein 3
5.37692 2.90386
CASZ1 Zinc finger protein cas-
tor homolog 1
5.03132 3.4185
RBBP4 Histone-binding pro-
tein RBBP4
4.97025 2.05424
BEND3 BEN domain-contain-
ing protein 3
4.75216 2.19638
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PGBD3 PiggyBac transpos-
able element-derived 
protein 3
4.70819 2.23163
GATAD2B Transcriptional repres-
sor p66-beta
4.50829 3.32597
MECOM MDS1 and EVI1 com-
plex locus protein 
EVI1
4.00392 2.05347
ZBTB10 Zinc finger and BTB 
domain-containing 
protein 10
3.53701 2.11845
C1QBP Complement compo-
nent 1 Q subcompo-
nent-binding protein
2.822 2.45405
PRR12 Proline-rich protein 12 2.51089 2.36333
25 most significantly enriched TTE-MBD2 interactors, identified after Ty1 
immunoprecipitation on both TTE-MBD2 and WT cells followed by mass 
spectrometry analysis. Results from triplicate pull-downs were analyzed with 
MaxQuant and label-free quantitation (LFQ) intensities were used to determine 
statistically enriched MBD2 interactors. Immunoprecipitation from wild type (WT) 
MCF-7 was used as a control.
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MBD2 is preferentially associated with CGI-promoters.
 In order to assess genome wide binding of MBD2 we isolated chromatin 
from TTE-MBD2 and WT MCF-7 cells, and performed ChIP sequencing. To preserve 
protein-protein interactions we stabilized the MBD2-NuRD complex on chromatin 
by applying a double crosslinking method [27]. Cells were first treated with 1.5mM 
disuccinimidil glutarate (DSG) before applying the standard formaldehyde fixation. 
Along with Ty1-tag antibody (Fig S1), we also used antibodies against MBD2 that 
became commercially available in the course of the study. ChIP-seq using the Ty1 
antibody on WT MCF-7 cells was performed as a negative control (data not shown) 
to correct for possible antibody cross-reactivity. One of the commercial MBD2 
antibodies showed the highest signal over background data compared to Ty1 ChIP 
and was subsequently used in the data analysis. MBD2 binding sites were identified 
using MACS 2.0 [28] with a p-value of 10e6 resulting in 8349 peaks. A pile-up heatmap 
showing quantitation of tags 5kb up- and downstream the center of MBD2 binding 
sites (Fig 2A left panel) revealed strong signal intensity, which is absent in the input 
(Fig 2A middle panel). A biological replica of a MBD2 ChIP-seq experiment revealed 
high reproducibility of the data (Fig 2A right panel). Specificity of the binding was 
validated by ChIP-qPCR on TTE-MBD2 and wild type MCF-7 cells using the MBD2 
as well as Ty1 antibody (Fig S1). The MBD2 binding sites with highest tag density 
were also enriched in Ty1 ChIP-seq using TTE-MBD2 but not in WT MCF-7 cells (Fig 
S2). 
 The genomic distribution of MBD2 binding sites was determined in comparison 
to a random set of genomic regions with the same average length, representative of 
the total genomic sequence distribution (Fig 2B). Genomic features such as intron, 
intergenic, exons and promoters were subsequently grouped accordingly to their GC 
content (Fig 2C). Binding preferentially occurs at CpG islands (CGIs) in particular at 
promoters and to a lower extent at exons as previously reported [24]. Representative 
examples of MBD2 binding are shown (Fig 2D). Strong binding is observed at the 
CGI promoter of KDM2 gene as well as at the CGI exons of MZF1, ZNF837 and 
ZNF497.
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Figure 2
Figure 2 Genome-wide binding of TTE-MBD2.
(A). Heatmap displaying tag densities in TTE-MBD2 (left and right) and input (middle) at MBD2 binding 
sites around 5kb up- and downstream of the center of the peaks. (B). Genomic location of peaks: each 
category is expressed as fold over random (y-axis), the random set consists of an equal number of sites 
having on average same length of the peaks. (C). CpG content of each category expressed as percent-
age of the total binding sites (y-axis). (D). Screenshots from the genome browser showing example of CGI 
promoters (KDM2A) and exons (MZF1, ZNF837, ZNF497) binding. 
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Methylation density plays a critical role in MBD2 binding.
 A large body of data strongly suggests that MBD2 specifically binds to 
methylated DNA in vitro [16,21] but evidence for its binding to methylated DNA in 
vivo was only recently obtained in mouse embryonic stem cells [24]. Therefore, we 
assessed the DNA methylation levels at MBD2 binding sites. Base pair resolution 
whole genome bisulfite sequencing (WGBS) was performed on MCF-7 cells as 
recently described [29]. Bisulfite conversion rate was around 99.9% and 51.4 mean 
coverage of CpG dinucleotides. The percentage of DNA methylation underneath 
MBD2 peaks was determined and compared with methylation levels at a random 
set of genomic regions matched for genomic distribution of MBD2 binding sites. 
MBD2 binding was clearly enriched at methylated genomic loci since more than 
80% of the binding sites had DNA methylation levels between 80-100% (Fig 3A), 
whereas in the random set the level ranges from 10 to 90%. In order to check 
the correlation between methyl-CpG density and MBD2 binding genome wide we 
binned the genome in 1kb windows and calculated MBD2 enrichment over input 
and methylation density within each window. Methylation density was expressed as 
the sum of methylated CpGs for each CpG dinucleotide normalized by length. Next 
we ranked the windows according to their methylation density (Fig 3B dashed line) 
and calculated MBD2 enrichment (green plot). A strong correlation between the two 
variables was detected as previously observed in mouse ESCs [24]. Figure 3C shows 
representative examples; the red track displays methyl-CpG density computed over 
50 bp windows across the genome. MBD2 peaks clearly coincided with increased 
methylation density as also exemplified for KCNN2, ZNF316, and ASCL5.
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Figure 3
Figure 3 Methylation state at MBD2 binding sites.
(A). Boxplot displaying methylation level at TTE-MBD2 binding sites compared to random (0=0% meth-
ylation, 1=100% methylation). (B). Genome wide correlation between TTE-MBD2 enrichment (green) 
and methylation density, calculated at 1kb windows ranked by methylation density (dashed line). (C). 
Screenshots from genome browser showing correlation between CpG methylation density (red track) 
and TTE-MBD2 peaks at KCNN2, ZNF316, and ASCL5.
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A subset of MBD2 binding sites marks active CpG island promoters
 To further characterize MBD2 binding sites we determined the epigenetic 
marks at the enriched loci, to gain insight into a putative role of MBD2 in gene 
regulation. We performed RNA polymerase II (Pol2), H2A.Zac and H3K4me3 ChIP-
seq in MCF-7 as well as strand-specific RNA-seq, while other data-sets were retrieved 
from the ENCODE project. Histone marks and transcription factors associated with 
active promoters (Pol2, H2A.Zac, H3K4me3, H3K36me3, H3K27ac) as well as 
enhancers (H3K27ac, P300), repressive marks (H3K27me3, H3K9me3) and methyl 
CpG (mCpG) levels were selected for this analysis. Note that the epigenetic profiles 
were generated in wild type MCF-7 cells, not in the line over-expressing TTE-MBD2.
 For each dataset we calculated tag densities 5kb up and downstream of the 
center of the MBD2 binding sites and performed k-means clustering to group the 
binding sites into distinct clusters. Heatmaps showing the output of the clustering (Fig 
4A) clearly depict 4 main clusters of binding sites. For this analysis we did not take 
into account directionality of transcription since the reference was the center of the 
binding sites. Two mirrored clusters were merged into cluster 4. Average profiles for 
each cluster (Fig 4B black lines) underpinned the distribution of the marks and their 
overall signal densities in each cluster. The 50th and 90th percentile of the distributions 
are also represented as a dark and light shadow respectively. Genomic distribution 
for each group was calculated (Fig 4C) together with average methylation levels and 
CpG density (Fig 4D). 
 The largest cluster, number 1, is comprised of MBD2 binding sites with a 
clear enrichment of DNA methylation and CpG density but no co-occurrence of any of 
the epigenetic marks analyzed. The binding sites are roughly equally distributed over 
CGI promoters, exons and intergenic regions (about 20% in each category). Cluster 2 
comprises MBD2 binding sites in CGI located in exons and introns. Interestingly this 
group of loci showed high levels of H3K36me3 and DNA methylation level was high 
up- and downstream the binding sites, probably reflecting gene body methylation 
pattern [30,31] 
Cluster 3 is a small cluster slightly enriched for CGI exons. Average methylation levels 
showed an asymmetric pattern, probably consistent with increased methylation at 
one flank of the binding sites. 
Interestingly, cluster 4 showed strong localized enrichment of marks associated 
to active transcription such as H3K4me3, Pol2, H3K27ac, H2A.Zac and low but 
appreciable levels of H3K36me3 as well as enrichment for P300. Interestingly, the 
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enriched signals are  positioned at one side of the MBD2 binding sites rather than 
coinciding with MBD2. Although cluster 4 represented a small subset of the total 
binding sites (1142/8349) it was interesting to find MBD2 co-occurring with active 
marks, in line with recent findings underlining that a fraction of MBD2 binding can 
mark also active promoters [23,32]. No enrichment was detected to co-occur with the 
histone marks H3K27me3 and H3K9me3, which are associated with transcriptional 
repression. The binding sites in cluster 4 were enriched for CGIs at transcription 
start sites (TSS-CGI) (420/1142). CpG density and methylation levels were also 
increased at these binding sites.
Representative examples from each cluster are shown (Fig S3): respectively the 
CGI promoters of FG2 (cluster 1) and ADHFE1 (cluster 2) and the CGI exons of 
KLF4 (cluster 3) and KCND3 (cluster 4).
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Figure 4
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Figure 4 (previous page) A subset of MBD2 binding sites associate with promoters enriched 
for active marks. 
(A). Heatmap of signal density using k-means clustering on TTE-MBD2 peaks (5kb up/downstream 
the center of MBD2 peaks) for TTE-MBD2, input, Pol2, H2A.Zac, H3K4me3, H3K27ac, H3K36me3, 
P300. The clustering shows four different groups of binding sites (numbers indicated on the right). 
H3K27me3 H3K9me3 and mCpG levels are not participating to the clustering itself but average signal 
density is calculated according to the clustering order. 
(B). Average profiles for each clusters of the indicated histone marks/transcription factors 5kb up and 
downstream the middle of each binding site, windows were divided in 20bp bin. The mean enrichment 
is shown using a black line and the 50th and 90th percentile are also displayed using a dark and light 
color respectively. 
(C). Genomic location of binding sites within each cluster was calculated as for Figure 2C. (D). Aver-
age methylation (black line) and average CpG density (red line) for all binding sites in each cluster, 
5kb up- and downstream the center of the peaks in 100bp window.
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MBD2 binding downstream of active promoters affects RNA Pol2 distribution. 
 The specific pattern of histone marks and Pol2 binding observed in cluster 
4 showed that MBD2 binds close to transcriptional start sites. Intriguingly, both the 
epigenetic marks and Pol2 were limited to a short and discrete genomic stretch 
that is not consistent with variable gene length. Our subsequent analysis excluded 
that we were dealing with short genes. Moreover MBD2 binding in WT MCF-7 cells 
was confirmed for a subset of loci, to exclude possible artifacts due to the over-
expression (Fig S4)
 To investigate the binding of MBD2 and its implication for transcriptional 
activity, we calculated the average tag density of the enriched features Pol2, 
and MBD2 relative to the TSS (Fig 5A) of the annotated promoters binding sites 
from cluster 4 (420/1142), together with CpG and methylation density (Fig 5B). At 
these 420 sites, MBD2 binding is located around 1kb downstream from the TSS. 
These promoters are enriched for Pol2 and are CpG dense. Next, we assessed 
the expression levels of the genes in the same cluster.  We first ranked all Ref-
seq annotated genes from highest to lowest in terms of RNA transcript levels and 
divided them into three bins (hereafter defined as “high”, ”medium” and “low”). We 
then compared our subgroup of genes in cluster 4 to overall expression levels. This 
analysis showed that the genes in cluster 4 are indeed expressed at low to medium 
levels (Fig 5C). A similar analysis was performed for H3K36me3 levels, ranking 
genes in three categories according to their H3K36me3. This analysis confirmed 
that genes downstream of the promoters in cluster 4 were active and displayed 
H3K36me3 levels nearly reaching that of medium expressed genes (Fig S5). 
 Given the gene expression levels and ChIP data, MBD2 binding sites of 
cluster 4 may prevent full transcriptional activation i.e. poises these promoters. 
Alternatively, MBD2 binding downstream of the main peak might block elongation 
of Pol2. Therefore we performed ChIP-seq for both WT and TTE-MBD2 cells 
with an antibody against the N-term of Pol2 (N-20) to determine Pol2 occupancy 
independently of the phosphorylation status of its C-terminal domain (CTD). At 
the TSS from cluster 4, Pol2 occupancy was slightly higher in the TTE-MBD2 as 
compared to the parental MCF-7 cells (fig 5D), which was supported by increased 
Pol2 using the CTD antibody (Fig S6). To study whether this phenomenon is in 
line with pausing, we determined Pol2 distribution during initiation and elongation 
by performing Pol2 ChIP-seq in TTE-MBD2 and WT MCF-7 cells with antibodies 
specific for phosphorylation at Ser5 (initiation) and Ser2 (elongation) of the CTD [33]. 
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If MBD2 binding affects pausing, the level of Ser5 at the promoter should be higher 
in TTE-MBD2 as compared to parental MCF-7 cells, instead we found the opposite 
(Fig 5E). Confusingly, we observed a decrease of the elongating Pol2 over gene 
bodies in the TTE-MBD2 that would be in line with pausing (Fig 5F). These results 
are consistent with the idea that MBD2 might induce a block in Pol2 elongation at 
these promoters.
 To shed light on these seemingly contradictory results, we investigated 
whether the sequence composition in cluster 4 promoters and downstream regions 
may provide an explanation.  It has recently been shown that CpG and methylation 
density in gene bodies has a modest negative correlation with elongation rate 
[34,35]. We therefore determined mCpG density over all genes, grouped them as 
previously into three classes (Fig S7 “high”, ”medium” and ”low”) and compared 
them with genes in cluster 4. The CpG density of cluster 4 genes over gene bodies 
was in the same range as those in the high CpG bin which was supported by the 
DNA methylation distribution (Fig S8). 
Note that in MCF-7 WT, that is in the absence of (over)expression of MBD2,  this 
class of promoters are already decorated with active marks (Fig 4A) and transcribed 
at low levels (Fig 5C) which may in part be due to their sequence composition and 
methylation density over the gene-body.  As the binding of MBD2 in TTE-MBD2 
cells did not change the level of transcription (data not shown), the epigenetic and 
transcription state of these genes are apparently not affected by MBD2 binding. 
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Figure 5
Figure 5 (previous page) MBD2 and Pol2 distribution at active promoters from cluster 4. 
(A). Average profile of Pol2 (MCF-7 WT) and MBD2 (TTE-MBD2) at promoters from cluster 4, calculated 
5 kb up- and downstream the TSS. (B). Average profile of CpG density, MBD2 and methylation levels at 
promoters from cluster 4, calculated 5 kb up- and downstream the TSS. (C): Boxplots showing RPKM 
values for all Ref-seq annotated expressed genes sorted and divided in 3 categories according to their 
transcript level, compared to RPKM values for genes annotated from cluster 4. (D). Average profile of 
N-term Pol2 at promoters from cluster 4, calculated 5 kb up- and downstream the TSS for TTE-MBD2 
and WT MCF-7. (E). As for 5D average profiles of Ser5 phosphorylated Pol2 at promoters from cluster 4, 
calculated 5 kb up- and downstream the TSS for TTE-MBD2 and WT MCF-7. (F). Average profiles of Ser2 
phosphorylated Pol2 over gene bodies downstream promoters from cluster 4, calculated 2 kb up- and 
downstream the TSS and the TES, for TTE-MBD2 and WT MCF-7. 
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MBD2 binds hyper-methylated hallmarks of cancer. 
 Most of the MBD2 binding sites in the MCF-7 breast cancer cell line were 
located at highly methylated promoters and exonic CpG islands that are rarely 
methylated in normal tissues. To investigate whether the observed MBD2 binding 
patterns could be a feature of breast cancers, we first checked the methylation status 
of all MBD2 bound regions in the HMEC cell line, a model of non-cancer human 
mammary epithelial cells [36]. In HMEC, methylation at regions bound by MBD2 (in 
TTE-MBD2 MCF-7) showed a very broad methylation range from 10 to 90% similar 
to a random distribution (Fig 6A) even though the global methylation level in HMEC 
is higher than in MCF-7 (Fig 6B). The specific methylation increase at CpG rich sites 
MBD2 sites and the global decrease compared to normal breast tissue is in line 
with reported aberrations in cancer methylome: a global hypo-methylation and local 
hypermethylation [37].  
 This prompted the question whether in primary cancers hypermethylation 
occurred at MBD2 binding sites as in MCF-7. Therefore, we calculated the methylation 
status at MBD2 binding sites in a large cohort of primary breast cancers (from TCGA: 
breast invasive carcinoma methylation data). We computed for each cancer sample 
as well as for a set of samples from healthy individuals included in this TCGA study 
the mean methylation levels at all MBD2 binding sites. The same analysis was 
performed for an equal number of random sites corrected for genomic distribution 
(as for Fig 3A). Interestingly, most of the tumor samples showed increased mean 
methylation at all MBD2 binding sites as compared to normal samples (Fig 6C), 
whereas increased methylation was not observed at random sites. 
We extended our analysis to MBD2 regions in cluster 4, comparing mean methylation 
levels at binding sites from this specific group between tumor and normal to mean 
methylation at all MBD2 sites (Fig 6D). Also in this case we observed a statistically 
relevant increase in methylation in the tumor versus normal at genomic location from 
cluster 4 (Mann-Whitney U p-value < 2.2e-16).
The relevance of increases DNA methylation at MBD2 binding sites for the etiology 
of primary breast cancer remains to be elucidated. Our findings indicate that MBD2 
is likely to bind to the MBD2 sites locations in primary cancer and may contribute to 
the regulation of transcription of the set of genes.
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CONCLUDING REMARKS
 Taken together our data suggest that MBD2 binds primarily at highly 
methylated regions, with a strong preference for CpG islands overlapping promoters. 
A small subset of promoters bound by MBD2 at a position downstream of the 
transcription start site (within 1 kb) is enriched for active marks and Pol2, and that 
these genes are expressed at low levels. We show that binding of MBD2 alters 
the Pol2 distribution: increase of Pol2 (phosphorylation independent), reduction 
of P-Ser5 at the region immediately downstream of the promoter and decrease of 
P-Ser2 in the remainder of the gene body. Our analysis also highlights that MBD2 
binding sites display increased methylation in primary breast cancer tissues as 
compared to normal samples or mammary epithelial cells. This suggests that MBD2 
may bind at these loci in breast cancer instigated by increased methylation. Analysis 
of MBD2 binding in cancer cells will be needed to determine its consequence on 
transcription and contribution to the etiology or maintenance of breast cancer.  
124
Chapter 4 Genome-wide binding of MBD2 reveals strong preference for highly methylated loci
Figure 6
Figure 6 Methylation levels of MBD2 binding sites in normal and breast cancer.
(A). Boxplot displaying methylation levels at TTE-MBD2 binding sites in MCF-7 and HMEC compared 
to methylation at random regions respectively in MCF-7 and HMEC. Random is corrected for genomic 
distribution as for Fig 3A. (B). Genome-wide methylation levels in MCF-7 and HMEC calculated in 50bp 
sliding windows. (C). Dot-plot showing mean methylation for each samples (#patients on X-axis) at all 
MBD2 binding sites: red dots are indicating mean-methylation at MBD2 sites in tumor samples (MBD2_
tumor) and green for healthy samples (MBD2_normal).  Same analysis at a random set of sites (as for Fig 
3A) for the two datasets is depicted in grey. On the y-axis methylation levels (0=0% methylation, 1=100% 
methylation). (D). As for Fig 6C dot-plot showing mean methylation for each samples (#patients on X-axis) 
at all MBD2 binding sites and at the subset represented in cluster 4.
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MATERIALS AND METHODS
Cloning and stable cell lines.
The pTTE retroviral vector was obtained as previously described. [38]
Full length MBD2 was PCR amplified from human MBD2 plasmid (image clone 
collection) and then cloned using EcoR1 and Xhol site to create pTTE-MBD2.
MCF-7 cells where transfected with the pTTE-MBD2 construct and single clones 
where selected with 1 µg/ml of puromycin. Cells were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal calf serum, 100 µl/ml 
Penicillin and 100 units/ml Streptomycin and 1 µg/ml puromycin at 37°C in 5% CO2. 
Antibodies and western blot .
Rabbit anti-MBD2 Antibody, Bethyl Laboratories , (A301-632), GAPDH (ab8245-100) 
and BB2 (against TY1 epitope) were used for Western Blot analysis. The same MBD2 
and BB2 together with H2A.Zac (acetyl K4+K7+K11, ab18262, sheep polyclonal, 
659355) from Abcam, Pol2 (8WG16 Monoclonal Antibody, Catalog Number MMS-
126R, Covance), H3K4me3 from Diagenode (pAb-MEHAHS-024, rabbit polyclonal, 
HC-0010), Ser5 Pol2 (phospho-CTD Ser-5, clone 3E8, Millipore Cat 04-1572) and 
Ser2 (phospho CTD Ser-2, clone 3E10, Millipore Cat 04-1571), N-term Pol2 (Pol 
II N-20 sc-899X SantaCruz) were used for ChIP-seq, Western blot analysis was 
performed according to standard procedure on whole cell lysates.  
Nuclear protein extraction and mass spec analysis.
Nuclear extracts from TTE-MBD2 and WT MCF-7 were prepared as previously 
described [39]. For the immunoprecipitation 500 μg of nuclear proteins were 
incubated over night at 4°C with 50μl protein A/G plus-agarose beads and 5μg 
BB2 antibody, each sample was prepared in triplicates. After washes samples were 
subjected to on-bead trypsin digestion as previously described [40] and prepared 
for mass spec analysis. Peptides were eluted from stage-tips with 2 x 20ul of 60% 
acetonitrile / 0.1% formic acid. Acetonitrile was evaporated using a speed vacuum 
centrifuge and the sample volume was brought to 15ul adding 0.1% formic acid. 5ul 
of peptide solution was loaded on a fused silica column (75um inner diameter, 30cm 
length) (Next Advanced) packed in-house with ReproSil-Pur C18-AQ 1.8 μm resin 
(Dr. Maisch) using a EASY-nLC II (Thermo Scientific). Peptides were eluted over 120 
minutes using a segmented gradient with increasing concentration of acetonitrile. 
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The column was kept at a temperature of 50°C using a column oven (Sonation). 
Eluting peptides were sprayed directly into a QExactive mass spectrometer (Thermo 
Scientific). The mass spectrometer was operated in data dependent TOP10 
sequencing mode. Target values for full MS scans were set to 3.000.000 and for 
MS/MS to 100.000 with maximum fill times of 20ms and 120ms, respectively. MS 
spectra were recorded at a resolution (m/z=400) of 70.000 and MS/MS spectra 
at a resolution of 17.500. Peptides were fragmented using higher energy collision 
induced dissociation (HCD) with NCE=25. The isolation window was set to 3Th. 
Singly charged peaks or peaks with charge state were excluded for sequencing. 
Dynamic exclusion was activated and the window was set to 20s. Data acquisition 
was performed using Xcalibur software. Data analysis was performed basically as 
described in [26] using the MaxQuant software package [41]. Statistical analysis was 
performed using Perseus and the interaction data was visualized using R
Double step-crosslinking and chromatin-immunoprecipitation.
Tagged-MBD2 ChIPs were performed with MBD2 Ab (A301-632) and BB2 (against 
Ty1) following a double step crosslinking method [42].
Cells were trypsinized and re-suspended with PBS to a final concentration of 8x106 
cells/ 500 μl PBS. Cell suspensions were crosslinked with 1.5mM DSG (disuccinimidyl 
glutarate, Thermo,  #20593) for 45’ at room temperature with gentle rotation. After 
two washes with 500 μl PBS, cell pellets were re-suspended in 1ml PBS and 1% 
formaldehyde was added for 10’ at room temperature.
Cross-linking was quenched with 125mM glycine and after two times ice-cold PBS 
washes, pellets were resuspended in 270 μl lysis buffer (50mM Tris pH8.0, 1%SDS, 
10mMEDTA protease inhibitor) and incubated 5’ on ice.
Sonication was performed for 15’-20’ with Bioruptor sonicator (NGS, Diagenode) 
and lysates were centrifuged at 13000rpm 4°C, for 5min.
20μl of Dynabeads protein A/G (Life Technologies) and 50μl of Dynabeads protein 
G were pre-incubated for 1h respectively with 4μl MBD2 and 5μg of BB2, in 1ml 
IP buffer (0.01%SDS,1.1% TritonX100, 1.2mM EDTA, 16.7mM Tris pH8.0, 167mM 
NaCl) by gentle rocking at 4°C.
After 1ml wash with IP buffer, antibody-loaded beads were incubated with 100μl 
chromatin, 100μl of 50mg/ml BSA in IP buffer, 800μl IP buffer and 1.25μl 10mg/ml 
yeast tRNA (Ambion  #AM7119) over-night at 4°C.
Beads were washed subsequently with 5 different buffers: one time with IP buffers, 
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two times with RIPA buffer (25mM TrisHCl pH 7.6, 150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS), two times with RIPA high salt buffer (1:10 mixture 
with 5M NaCl), one time with LiCl wash buffer (2mM EDTA, 20mM Tris pH 8, 250mM 
LiCl, 1% NP-40, 1% sodium deoxycholate) and two times with TE buffer.
Beads were resuspended in 50μl freshly prepared elution buffer (1%SDS, 0.1M 
NaHCO3) supplemented with 5mM DTT and incubated for 45’ at 65°C in a 
thermomixer. 
Supernatants were collected and beads were re-suspended once more with 50μl 
fresh elution buffer, the two supernatants were joined, supplemented with 300mM 
NaCl 0.5μl RNase cocktail and de-crosslinked for 4 hours at 65°C, shaking.
After addition of 2 μl 1M Tris pH6.8 and 2 μl 20mg/mL proteinase K samples were 
incubated at 65°C for 1 more hour.
DNA was purified with QIAGEN columns, and 2-5μg were used for library preparation 
and sequencing. 50 μl from TTE-MBD2 chromatin was also de-crosslinked and 
prepared for sequencing (referred as input chromatin).
For all the other chromatin-immunoprecipitations cells were fixed for 10 minutes 
at room temperature by the addition of formaldehyde to a final concentration of 
1%, after which glycine was added to a concentration of 100 mM. Cells were then 
washed twice with PBS and collected into lysis buffer (150 mM NaCl, 20 mM Tris pH 
8.0, 2 mM EDTA, 1% triton X-100, protease inhibitor [complete EDTA free, Roche, 
04 693 132 001], 100 mM PMSF). The lysate was sonicated to an average of 300-
500bp fragments. The resulting sonicate was centrifuged at 4000×g for 5 minutes, 
an aliquot of 10% retained for input and the remaining material transferred to a 
fresh tube. 20 μl protein G or protein A/G magnetic beads were pre-incubated with 
the different antibodies for 4 hours and after washing away the excess of antibody, 
chromatin was added O.N at 4°C.
Afterwards, the complexes were washed, then reverse crosslinked for a minimum 
of 4 hours at 65°C. Recovered DNA was then purified using a Qiaquick spin column 
and eluted in 50 of 10 mM Tris pH 8.0. 
Strand specific RNA (ssRNA) preparation was performed as previously described 
[43]. 
Illumina high-throughput sequencing and data analysis.
Libraries were prepared according to manufacturer’s standards. Briefly 5-10 ng 
DNA was subjected to end repair using Klenow DNA polymerase, T4 ligase and T4 
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polynucleotide kinase (T4 PNK). A 3′ protruding A base was generated using Taq 
polymerase and Illumina adapters (GAIIX) or NEXTflex adapters (HiSeq2000) were 
ligated. The DNA was loaded on E-gel for size selection (300 bp), further amplified 
by PCR and used for cluster generation on the Illumina GAIIx or HiSeq2000 genome 
analyzer. The 36 (GAIIx) or 43 bp tags (HiSeq2000) were mapped to the reference 
human genome hg19 (NCBI build 37), using the BWA allowing one mismatch. Only 
uniquely mapped-reads were used for data analysis and visualization.
Peak-calling was performed with MACS 2.0 tool against a reference input sample 
from the same cell line (TTE-MBD2). Genomic distribution of peaks or random 
regions was performed with a script that annotates binding sites according to all 
RefSeq genes, taking into account 4 functional categories: promoters (1kb up or 
downstream the TSS), exons, introns and intergenic. The random set consists of an 
equal number of sites having on average same length of the peaks. Each category 
is subsequently grouped in “CGI” or “non-CGI” according to the overlap with CpG 
islands. The assignment is non-overlapping, peaks are only assigned to a category 
once and the above order is hierarchical. Whole genome bisulfite sequencing data 
were analyzed as previously described [29]. Cytosine methylation levels within CpG 
context are present in the MCF-7_CpG_methcounts.bed.gz file and are used to 
calculate methylation levels (between 0=0% methylation and 1=100% methylation) 
and mCpG density per 1kb genomic window.
Heatmaps and k-mean clustering together with relative average profiles (Fig 4B) 
were performed using a Python package available at http://simonvh.github.io/fluff/. 
ChIP-seq datasets used for generating average profiles and comparisons between 
WT and TTE-MBD2 were normalized for total number of uniquely mapped-reads. All 
average profiles are obtained counting tags (or methylated CpG) per 100bp windows.
For gene expression analysis RPKM values were calculated from RNA-seq data and 
only expressed genes were taken into account. For H3K36me3 levels the number of 
tags per bp were computed over the gene bodies on all Ref-seq annotated genes.  
For Ser2-P average profiles over gene bodies downstream promoters from cluster 4 
only genes longer than 4kb were taken into account. Same criteria were followed to 
compute mCpG density (Fig S7-8).
R was used to generate most of the graphs.
The data generated for this work have been deposited in NCBI’s Gene Expression
Omnibus and are accessible through GEO Series accession number GSE54693.
The rest of the ChIP-Seq datasets (H3K27ac; H3K36me3; P300; H3K27me3; 
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H3K9me3) were retrieved from the ENCODE data repository site (http://genome.
ucsc.edu/ENCODE/).
Acknowledgements: We thank I. Gut and M Gut for technical support in the whole 
genome bisulfite sequencing.
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SUPPORTING INFORMATION
Supporting informations including eight figures and one table are available online at 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0099603#s5
SUPPLEMENTAL FIGURES
Figure S1: ChIP qPCR for MBD2 ChIP on WT, TTE-MBD2 and Ty1 ChIP on TTE-MBD2 at some 
representative binding sites. The y-axis shows recoveries expressed as % of input.
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Figure S2: Heatmap dis-
playing tag densities in 2 
MBD2 ChIP-seq replica on 
TTE-MBD2, Ty1 ChIP on 
TTE-MBD2 (“Ty1”) and WT 
(“Ty1 control”) and input at 
TTE-MBD2 binding sites 
around 5kb up and down-
stream the center of the 
peaks.
Figure S3 Screenshots from the genome browser with examples from each cluster.
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Figure S4 ChIP qPCR for MBD2 ChIP on WT and TTE-MBD2 tested at 1kb downstream of a set of loci 
from cluster 4.
Figure S5 (left) As for Fig 5C boxplots showing 
H3K36me3 tag densities for all Ref-seq annotated genes sorted and divided in 3 categories according 
to H3K36me3 levels, compared to H3K36me3 density for genes downstream annotated promoters in 
cluster 4. 
Figure S6 (right) Average profiles of Pol2 (using the antibody against CTD, 8WG16) at promoters from 
cluster 4, calculated 5 kb up- and downstream the TSS for TTE-MBD2 and WT MCF-7.
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Figure S7 Boxplots showing mCpG densities for all Ref-seq annotated genes sorted and divided in 3 cat-
egories according to mCpG density, compared to density in genes downstream promoters from cluster 4.
Figure S8 Average methylation levels calculated 2 kb up- and downstream the TSS and the TES, for 
gene bodies downstream promoters from cluster 4 (as Fig 5F), and for the “high” bin (Fig S7) with highest 
mCpG density.
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ABSTRACT 
The MBD2/NuRD complex, which is generally known to be associated with 
repression of transcription, has been shown to occupy genomic loci containing high 
levels of DNA methylation. In addition, a small cluster of NuRD-bound loci have low 
levels of DNA methylation. The binding to methylated loci can be explained by the 
presence of the methyl-CpG binding MBD2 protein in the complex. How the NuRD 
complex is recruited to non-methylated loci, however, remains unclear. Here, we use 
quantitative mass spectrometry-based proteomics to show that the ZMYND8 protein 
bridges the NuRD complex to a number of putative DNA binding zinc finger proteins, 
ZNF687, ZNF592 and ZNF532. ZMYND8 most likely directly interacts with the NuRD 
complex subunit GATAD2A, which is mutually exclusive with GATAD2B, through 
its conserved MYND domain. Furthermore, ChIP-sequencing analyses reveal that 
ZMYND8 and MBD3 share a subset of genome wide binding sites, which mostly 
map to active promoters and enhancers. We thus hypothesize that the ZMYND8/
ZNF module recruits the GATAD2A/NuRD complex to a subset of hypomethylated, 
transcriptionally active target sites in the genome. 
 
143
ZMYND8 interacts with NuRD through its MYND domain and co-localizes with MBD3 on a 
subset of its target genes 
INTRODUCTION
 
 The Nucleosome Remodeling and histone Deacetylase complex (NuRD) is 
a highly conserved chromatin remodeling complex which is generally known to be 
associated with transcriptional repression. This multi-subunit complex contains two 
catalytic activities: the ATP dependent chromatin remodeling enzymes CHD3, CHD4, 
and CHD5 [1, 2] and the histone deacetylases HDAC1 and HDAC2. In addition to 
these catalytic activities, NuRD contains either MBD2 or MBD3, which are proteins 
containing a Methyl-CpG Binding Domain. However, multiple studies have shown 
that mammalian MBD3 lacks methyl-C binding affinity [3, 4]. Additional subunits of 
the NuRD complex are GATAD2A and GATAD2B; MTA1, MTA2 and MTA3; RBBP4 
and RBBP7; and CDK2AP1 [1, 5]. Although Smits et al. recently determined the 
stoichiometry of the complex [6], questions remain regarding which subunits are 
mutually exclusive to each other and how many different functional compositions of 
the complex exist. 
The domains and enzymatic activities in the NuRD complex are generally 
associated with repression of transcription, although until now this repression has 
mostly been shown on reporter genes in transactivation assays [7, 8]. For example, 
the CHROMO domains present in CHD3, 4 and 5 bind to H3K4me0 and H3K9me3 
[9, 10] and the HDACs remove histone acetylation. 
Recently, two groups have published Chromatine immuno-precipitation 
followed by high-throughput sequencing (ChIP-seq) datasets for both MBD2 and 
MBD3 [11, 12]. The ChIP-seq profile of MBD2 in mouse embryonic stem cells 
shows two distinct MBD2 clusters.  One cluster correlates with high levels of DNA 
methylation on CpG islands and in gene bodies, while the other, much smaller 
group localizes to non-methylated promoters and overlaps with the Mbd3 and Chd4 
profiles [12]. The Renkawitz data also show a correlation between MBD2 binding 
and high DNA methylation levels, while the MBD3 peaks show an anti-correlation 
with DNA methylation [11]. Although these ChIP-seq datasets have revealed NuRD 
target genes in different cell types, the question remains how NuRD is recruited to 
promoters which lack DNA methylation.
In previous reports, we and others have identified a number of 
substoichiometric interactors of the NuRD complex, including ZMYND8 and 
ZNF687 [6, 9, 13]. The ZNF687 protein contains 10 C2H2-type zinc fingers. Zinc 
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finger domains chelate Zinc and often function as (sequence-specific) DNA binding 
domains or protein-protein interaction domains. ZMYND8 has a completely different 
domain architecture with a PHD finger, BROMO domain and PWWP domain at its 
N-terminus, and a MYND domain located closer to the C-terminus [14]. This protein 
is also called Protein Kinase C- Binding Protein (PKCBP1) or RACK7 [15]. 
Here, we show that ZMYND8 directly binds to the NuRD complex through 
its conserved MYND domain. Furthermore, we show that GATAD2A and GATAD2B 
assemble in mutually exclusive NuRD sub-complexes. ZMYND8 purifications only 
enrich for GATAD2A/NuRD, which is a strong indication that GATAD2A is the direct 
interaction partner of the MYND domain. Finally, we show that ZMYND8 and MBD3 
share a subset of genome wide non-methylated loci, suggesting that ZMYND/
ZNF592/ZNF587 recruits GATAD2A-containing NuRD complexes to a subset of its 
target genes. Interestingly, the enhancers and promoters bound by ZMYND8 and 
MBD3 are decorated with histone modifications which are commonly associated 
with active transcription. 
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RESULTS
ZMYND8 is a sub-stoichiometric interactor of the MBD3/NuRD complex.
 Recently, we and others have identified ZMYND8 as a novel putative 
interactor of the NuRD complex [6, 9, 13]. To identify ZMYND8 and MBD3 interactors 
in HeLa cells, we performed SILAC-based GFP-affinity purifications [16, 17]. NuRD 
core subunits were convincingly enriched in the MBD3-GFP purification (Figure 1A), 
as well as some ZNF proteins and the known NuRD interactor SALL4. In contrast, 
purification of GFP-ZMYND8 resulted in the identification of, multiple protein 
complexes. In addition to NuRD, BHC (consisting of LSD1, RCOR1-3, PHF21A 
and HMG20B) and EMSY were all significantly enriched. This is in agreement with 
the data obtained by Malovannaya et al. [13], who identified the ZMYND8 protein 
as a central hub in a large transcription regulation network (Figure 1B). Finally, in 
the GFP-ZMYND8 purification, three zinc finger proteins were enriched which have 
together been described as the Z3 module [13].
ZMYND8 links the Z3 module to the NuRD complex
To  investigate which protein mediates the interaction between the NuRD 
complex and the Z3 hub, we performed label-free quantification (LFQ) purifications 
of GFP-MBD3 from stable cell lines containing either a scrambled shRNA or an 
shRNA targeting ZMYND8, ZNF687 or CDK2AP1 (Figure 1C) [18]. We obtained 
iBAQ values from these purifications, which we used to calculate the stoichiometry of 
the core subunits of the NuRD complex and its interactors (Figure 1D) [6]. The three 
ZNFs share a number of tryptic peptides and thus cannot be distinguished in iBAQ-
based stoichiometry determination. Therefore, we calculated the total intensity of the 
peptides unique to each of the ZNF proteins in each of the purifications (the unique 
intensity). Then, we divided these by the summed intensity of all identified peptides 
in the same sample to correct for concentration differences between the samples. 
Next, we compared these corrected unique intensities to those in the scrambled 
knock-down, which resembles the wild-type situation (Figure 1E).
Although the knock-downs in the respective lines were only partial (data not 
shown), we were able to show an effect of each knock-down on the fraction of the 
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Z3 complex that is associated with NuRD. Knock-down of CDK2AP1, which often 
shows a very high ratio in ZMYND8 purifications suggestive of a direct interaction, 
did not have any effect on the stoichiometry of ZMYND8 or any of the zinc fingers. 
In contrast, knock-down of ZMYND8 reduced the levels of the zinc fingers in the 
purified sample by about 50% (p < 0.05, Figure 1E). Finally, knock-down of Znf687 
significantly reduced the levels of NuRD-associated ZNF687 protein itself, whereas 
the levels of the other ZNF proteins and ZMYND8 were not affected. In summary, 
these results indicate that ZMYND8 mediates the interaction between NuRD and 
ZNF687, -532 and -592.
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The MYND domain is required and sufficient for interaction with NuRD
Since ZMYND8 mediates the interaction between the ZNF proteins and 
NuRD, we set out to identify the domain that is required for these interactions. 
ZMYND8 contains three domains that may be involved in histone-tail binding: a 
PHD finger, a BROMO domain, and a PWWP domain. In addition to these domains, 
ZMYND8 has a MYND (MYeloid, Nervy and Deaf) domain, which is a well-conserved 
protein-protein interaction domain [19]. 
Using a label-free quantification method to purify full-length ZMYND8 and 
deletion mutants lacking either one of these domains revealed that the MYND 
domain-deletion mutant does not interact with co-repressor complexes (Figure 2A 
and B). A heatmap of the LFQ values of interactors in purifications of the different 
deletion mutants shows a loss of NuRD and BHC intensity in the purification of the 
MYND deletion mutant only. In contrast, the intensity of the Z3 module is similar in 
the ZMYND8 purifications, indicating that this interaction is not mediated by any of 
the domains. Calculation of the stoichiometry of the NuRD and BHC core subunits 
shows remarkably stable values for a transient transfection-based purification (Figure 
2C). The only mutant showing clearly deviating values is the ΔMYND mutant. These 
data thus show that the ZMYND8 MYND domain binds to co-repressor complexes 
whereas this domain is not required for the interaction between ZMYND8 and the 
ZNF proteins.
Having established that neither the PHD or BROMO domain are required 
for the interaction between ZMYND8 and NuRD, we wanted to further test the 
Figure1:  ZMYND8 mediates the interaction between the Z3 module and NuRD. A. SILAC-based 
purification of GFP-MBD3 shows all NuRD subunits and a number of substoichiometric interactors. B. 
SILAC-based purification of GFP-ZMYND8 shows subunits of different co-repressor complexes. NuRD 
and BHC complex subunits are indicated by blue and green, respectively. ZNF proteins belonging to the 
Z3 module are indicated in orange. C. Schematic representation of the LFQ-based GFP-purifications from 
HeLa cells inducibly expressing MBD3-GFP and having a shRNA mediated knock-down of CDK2AP1, 
ZMYND8 or ZNF687. As a control, purifications are performed using a cell line expressing a scrambled 
shRNA. Purifications are performed in triplicates. D. Stoichiometry determination for NuRD subunits 
based on the LFQ purifications, according to [6]. The stoichiometry of the complex is stable in the various 
knock-down lines, except for CDK2AP1, which shows a lower stoichiometry in the CDK2AP1 knock-
down line as expected. E. Comparison of the summed intensities of peptides for unique each of the ZNF 
proteins in the MBD3 purifications from each of the knock-down lines. Error bars in D. and E. indicate 
standard deviation. * p< 0.005, ** p< 0.01.
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requirements of the MYND-domain. In a SILAC-based purification of ZMYND8-
ΔMYND, lacking only the MYND domain, all interactions with NuRD and BHC were 
lost (Figure 2D), showing that the MYND domain is required for the interaction. 
To test whether the MYND domain is also sufficient for the interaction with 
NuRD, we performed SILAC GFP affinity purifications using a GFP-MYND construct 
containing the C-terminus of ZMYND8. This purification resulted in interactions with 
both NuRD, BHC, as well as the Z3 proteins (Figure 2E). In conclusion, the MYND 
domain is required and sufficient for ZMYND8 to interact with the co-repressor 
complexes. The interaction surface for the zinc finger proteins within the ZMYND8 
protein is less clear. 
Since the PHD, BROMO and PWWP deletion mutants did not affect the 
interaction between NuRD and ZMYND8, we set out to test if they are indeed 
involved in binding to histone modifications. To this end, biotinylated synthetic 
peptides representing the first 17 amino acids of the H3-tail, with and without known 
histone modifications, were coupled to streptavidin beads and incubated with 
nuclear extract containing different deletion mutants. As shown in Figure 2F, full 
length ZMYND8 specifically recognizes H3K9,14Ac but not when H3 is methylated 
at K4. This repulsion by H3K4me3 is also observed in the context of non-acetylated 
peptides. The PHD finger of ZMYND8 is most likely responsible for the recognition of 
non-modified H3K4. However, deletion of this domain also diminishes binding to the 
H3K9,14Ac peptide, probably due to the reduced stability or disturbed conformation 
of the PHD-BROMO module. Interestingly, binding to unmodified H3 is maintained 
in the BROMO-domain deletion mutant, whereas H3K9,14Ac binding is lost. 
Binding of the ΔMYND-mutant to the unmodified H3 and the H3K9,14Ac peptides 
shows very clearly that this binding occurs independently of the NuRD complex. 
Notably, unmodified H3 and H3K9,14Ac binding can also be observed for the 
endogenous ZMYND8 protein, whereas TAF3 clearly prefers binding to H3K4me3 
and H3K4me3K9,14Ac peptides (Figure 2G). The PWWP domain is expected to 
bind H3K36me3 [20], but further experiments are needed to investigate this.
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GATAD2A and B are mutually exclusive and ZMYND8 only binds GATAD2A/
NuRD
Close inspection of the SILAC-based GFP-purifications of ZMYND8-FL and 
ZMYND8ΔMYND revealed that in most cases all paralogues of each NuRD subunit 
are specifically enriched. The exception to this are the GATAD2 paralogues of which 
only GATAD2A co-purifies with ZMYND8. This protein shows the highest enrichment 
ratios in most of the ZMYND8 purifications. Smits et al. have determined that the 
NuRD complex contains two GATAD2 molecules per complex [6], but whether 
GATAD2A and GATAD2B can form heterodimers is not clear. Since our purifications 
suggest that ZMYND8 only interacts with GATAD2A, we purified GFP-GATAD2A and 
GATAD2B-RFP using SILAC-based quantitative proteomics.
The GATAD2A purification resulted in identification of most NuRD subunits, 
as well as ZMYND8, ZNF687 and ZNF592 (Figure 3A). However, whereas GATAD2A 
had a log2(h/l) ratio of ~8, GATAD2B was identified as a background binder. Comparing 
the ratios of the unique and shared peptides of these two proteins shows clearly that 
GATAD2A containing complexes do not contain GATAD2B (data not shown). The 
purification of GATAD2B-RFP again shows specific enrichment of all NuRD subunit 
paralogues, except for GATAD2A (Figure 3B). The ZMYND8 and ZNF proteins were 
probably so low abundant in this purification that they were not even identified. This 
Figure 2: MYND domain is required and sufficient for the interaction with the transcription 
regulation complexes. A. Heatmap showing the average LFQ intensities of the ZMYND8 interactors 
(indicated on the right) in GFP purifications of different ZMYND8 deletion mutants (indicated on the top). 
The intensity of the Z3 module is equal in all purifications, but the intensities of subunits of both the NuRD 
and BHC complexes are lower in the ZMYND8ΔMYND mutant. B. Schematic representation of the GFP-
fused domain-deletion mutants of ZMYND8. C. Stoichiometry of NuRD and BHC subunits derived from 
the LFQ-based GFP purifications of the ZMYND8 deletion mutants. Error bars indicate standard deviation. 
A clear loss of interaction can be observed for all subunits of the NuRD and BHC complexes in the 
ZMYND8ΔMYND mutant. D. SILAC-based GFP purification of ZMYND8ΔMYND, showing only ZNF687, 
ZNF592 and some histone proteins as interactors. E. SILAC-based GFP purification of ZMYND8MYND 
only. Specific enrichment of most NuRD and BHC complex subunits is observed. F. Affinity enrichments 
with immobilized histone-tail resembling peptides (indicated at the top) in nuclear extracts from cells 
expressing GFP-ZMYND8-FL or one of the deletion mutants. Full-length ZMYND8 strongly binds to 
H3K9,14Ac peptides and to a lesser extent to the unmodified H3 peptide. Deletion of the PHD or BROMO 
domain diminishes binding to the acetylated peptide, whereas deletion of the MYND domain does not 
affect binding to the peptides. G. As in F. but the western blot was performed with anti-ZMYND8 or anti-
TAF3 antibody.
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is strong evidence that GATAD2A and GATAD2B are mutually exclusive and thus 
form homodimers only. Furthermore, ZMYND8 only interacts with the GATAD2A/
NuRD complex, most likely via the GATAD2A protein itself. If ZMYND8 would directly 
bind to another NuRD subunit, which all can interact with both GATAD2A as well as 
GATAD2B, no GATAD2A/NuRD specific binding of ZMYND8 could be observed. 
GATAD2A has conserved MYND interaction motifs
 The fact that ZMYND8 exclusively interacts with GATAD2A/NuRD and not 
with GATAD2B/NuRD suggests that ZMYND8 binds directly to a motif present in 
GATAD2A which is lacking in GATAD2B. 
Multiple publications about the structure and interactions of MYND domains suggest 
that this domain may recognize different aminoacid motifs [19, 21, 22]. Ansieau et al. 
described that the MYND domain from ZMYND11 binds PxLxP motifs, while the same 
study shows that ZMYND8 does not bind to this aminoacid sequence [19]. However, 
the protein fragment used for recombinant expression and interaction studies may 
have been too small to achieve the required conformation. Liu et al. described how 
the MYND domain of ETO (also called ZMYND2) recognizes a PPPLΦ motif in 
N-CoR [21]. So, although the sequence of the MYND domain of ZMYND8 is more 
similar to the MYND domain of ZMYND11, we set out to find PPPLΦ motifs in NuRD 
core subunits. 
Interestingly, GATAD2A contains three consensus PPPLΦ motifs, while 
GATAD2B lacks these motifs (Figure 3C, indicated in bold). We performed 
phylogenetic analysis on the GATAD2A and B proteins of the most commonly 
used model-organisms, representing vertebrates (mammal, fish, amfibia, bird) and 
invertebrates (insect and roundworm). Interestingly, whereas most vertebrates 
contain two GATAD2 paralogues, zebrafish has only one Gatad2ab gene, similar to 
invertebrates. However, this Gatad2ab protein has the putative motifs required for 
the interaction and therefore it clusters with all the GATAD2A genes (Figure 3D). In 
conclusion, this analysis might hint towards occurrence of the PPPLΦ motif during 
early vertebrate development, coinciding with the presence of DNA methylation 
[23]. However, inclusion of many more species in the analysis is required for a solid 
statement and more research is required to investigate whether this PPPLΦ motif is 
indeed required for the interaction with the ZMYND8 MYND domain.
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Figure 3: ZMYND8 interacts only with the GATAD2A/NuRD complex which is mutually exclusive 
with GATAD2B-containing NuRD. A. SILAC-based GFP purification of GATAD2A shows enrichment of 
all NuRD subunits, with the exception of GATAD2B. In addition, ZMYND8, ZNF687 and ZNF592 are co-
purified. B. SILAC-based RFP purification of GATAD2B showing specific enrichment of all NuRD subunits, 
with the exception of GATAD2A. C. Sequence alignment of GATAD2A and GATAD2B from different model 
organisms reveals the GATAD2A-specific presence of three PPPLΦ motifs (bold). D. Phylogenetic tree of 
GATAD2 paralogues from multiple model organisms reveals clustering of the zebrafish Gatad2ab protein 
with the PPPLΦ -containing GATAD2A proteins of other vertebrate species. 
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ZMYND8 and MBD3 genome-wide occupancy at active promoters and 
enhancers
 
 To investigate whether ZMYND8 and MBD3 also functionally interact with 
each other in vivo, we performed ChIP-seq experiments to determine genome-wide 
occupancy patterns (Figure 4A). We used antibodies against endogenous proteins 
and chromatin derived from doubly cross-linked HeLa cells. ZMYND8 ChIP-seq 
resulted in the identification of roughly 5000 peaks. A heatmap centered on the 
ZMYND8 peaks shows a high correlation with the MBD3 genome wide occupancy 
(Figure 4B). The peaks are divided in three clusters. Based on co-occurring histone 
modifications, cluster 2 consists of active gene promoters. Clusters 1 and 3 overlap 
for about 53% with active enhancers, as defined by the presence H3K4me1 and 
H3K27Ac and DNAseI hypersensitive sites (Figure 4C). The Renkawitz and Schübeler 
groups have mainly shown MBD3/NuRD binding at non-methylated promoters [11, 
12], so it is unclear what the role of ZMYND8 at the enhancers could be. ChIP-
sequencing in a genetic CRISPR-based ZMYND8 knock-out HeLa cell line confirms 
that all peaks observed with the endogenous ZMYND8 antibody are specific (Figure 
4B: ZMYND8 KO).  
In conclusion, genome wide binding studies of ZMYND8 and MBD3 reveals 
extensive overlap between these proteins at active promoters and enhancers, 
suggesting a functional link in vivo. 
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Figure 4: ZMYND8 and MBD3 co-occupy active promoters and enhancers. A. A screenshot of 
the UCSC browser showing co-localization of ZMYND8 and MBD3 on the TXLNA promoter, which is 
decorated with H3K4me3 and H3K9,14Ac. Two replicates for ZMYND8 and MBD3 endogenous ChIPs 
are indicated by r1 and r2. The signal for ZMYND8 is almost completely lost in ZMYND8 knock-out 
cells (ZMYND8_KO). B. Heatmap centered on ZMYND8 peaks in replicate 2 shows a clear correlation 
between ZMYND8 and MBD3 peaks. Cluster 2 consists mainly of H3K4me3 and H3K9Ac rich promoters, 
whereas ~53% of clusters 1 and 3 overlaps with active enhancers (C.), based on presence of DHS, 
H3K4me1 and H3K27ac and absence of H3K4me3.
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DISCUSSION 
  In this study we have characterized the interaction between ZMYND8 and 
the NuRD complex, which was previously reported to be sub-stoichiometric [6, 9]. 
We show how ZMYND8 mediates an interaction between the putative DNA binding 
Z3 module and different corepressor complexes, such as NuRD and BHC. We have 
determined that the MYND domain is required and sufficient for the interaction 
between ZMYND8 and co-repressor complexes. This domain likely binds to the 
three PPPLΦ motifs present in the GATAD2A protein, since we found ZMYND8 to be 
associated exclusively with GATAD2A/NuRD. A schematic model of the confirmed 
and hypothetic interactions is shown in Figure 5.
 Malovannaya et al. described multiple other complexes as interactors of 
ZMYND8, but we did not identify complexes other than NuRD, BHC and EMSY/Sin3 
in HeLa cells [13]. A possible explanation for this discrepancy may be the use of 
nuclear versus whole cell extracts. One of the proteins described to be a structural/
constitutive binder of ZMYND8 is TSPYL [13] which we did identify. However, in our 
analysis, this protein displayed a much lower stoichiometry than the NuRD core 
subunits. 
   Although MBD3 purifications identified only ZMYND8 and the Z3 module as 
NuRD interactors, we observed both the NuRD and the BHC complex in ZMYND8 
purifications. This implies that ZMYND8 binds to either NuRD or BHC in a mutually 
exclusive manner, which is in agreement with the fact that both NuRD and BHC 
require the MYND of ZMYND8 for the interaction. 
We have collected evidence to support our hypothesis that the ZMYND8 
MYND domain binds to GATAD2A. Evolutionary analysis shows that a number of 
putative MYND-interaction motifs (PPPLΦ) in the GATAD2A protein are conserved 
from mammals to fish. In addition, our mass spectrometry experiments have 
shown that GATAD2A, but not GATAD2B, is specifically enriched in GFP-ZMYND8 
purifications. Together with interaction data for GFP-GATAD2A and B showing that 
these proteins are mutually exclusive within NuRD, this suggests that ZMYND8 may 
only recruit GATAD2A/NuRD complexes.    
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Genome wide localization of ZMYND8 and MBD3
To confirm our hypothesis that the ZNF module recruits NuRD to certain 
target genes, we performed ChIP-seq for endogenous MBD3 and ZMYND8. Indeed, 
these proteins show a significant overlap in genome wide occupancy, suggesting 
that they interact in vivo as well. However, MBD3 ChIP-sequencing should be 
performed in wild-type and ZMYND8 knock-out cells to unambiguously establish 
MBD3 recruitment to these loci by ZMYND8. 
The loci bound by ZMYND8 and MBD3 are mainly active promoters and 
enhancers that are also enriched for H3K4me3 and H3K9,14Ac or H3K4me1 
and H3K27Ac, respectively. No enrichment of MBD3 on heterochromatic loci was 
observed. However, in vitro binding assays have shown that ZMYND8 preferentially 
binds H3K9,14Ac when H3K4 is not modified. Even on non-acetylated peptides, 
ZMYND8 specifically binds non-methylated H3K4, but still binds weakly to H3K4me1. 
The apparent co-occurrence of ZMYND8 and H3K4me3 in vivo can be explained in 
multiple ways. First of all, ChIP-seqencing only shows correlations. Observed signals 
are based on populations of cells, so the two enriched marks do not necessarily co-
exist on one nucleosome or could even exist on the two different H3-tails protruding 
from one nucleosome. Second, the NuRD complex contains many additional histone 
binding domains that may guide it to promoters. Third, the specific localization to 
promoters could also be based on DNA sequence binding by the Z3 modules. 
Applying ChIP-reChIP may give an answer to some of these questions and could 
reveal which histone modifications coincide with ZMYND8 binding to nucleosomes. 
However, whether both K4 and K9 on a single histone tail are modified cannot be 
resolved using this technique. Furthermore, ZMYND8 ChIPs are very specific but 
have a very low efficiency, which makes ChIP-reChIP very difficult. Additionally, 
performing ZMYND8 ChIPs in ZNF knock-out cells may reveal whether the genome-
wide ZMYND8 binding is driven by sequence-specific binding of the Z3 module or 
by specific recognition of histone modifications. Most likely, an interplay between 
these two determines genome-wide ZMYND8 binding. Whereas DNA binding by the 
Z3 module may be important to achieve binding specificity, the interaction between 
ZMYND8 and acetylated histone tails may stabilize the protein on chromatin. 
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Figure 5: Hypothetic model of NuRD recruitment by ZMYND8. A schematic model showing sequence-
specific DNA binding by the Z3 module and histone-tail binding by ZMYND8. Furthermore, ZMYND8 
mediates the interaction between the Z3 module and the NuRD complex, by directly contacting GATAD2A 
with its MYND domain. 
Figure 5
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MATERIALS AND METHODS
Cloning
ZMYND8-FL was PCR amplified from the Thermo Scientific cDNA clone 9052809/
MHS1768-213246149 and ligated into pEGFP-C3 using HindIII and BamHI. This 
cDNA clone lacks some amino acid stretches, but no functional domains. Deletion 
mutants were made by a 3-point ligation of two PCR products.  The vector was dige-
sted using HinDIII and BamHI, whereas the inserts had either HinDIII and SalI (for 
N-terminal part) or SalI and BamHI (for C-terminal part) restriction sites. GFP-GATA-
D2A was constructed by PCR from a pool of cDNA and ligation into the pEGFP-C3 
vector. pcDNA5-FRT-TO-MBD3-GFP was created by Gateway cloning.
Cell culture and transfection
Hela Kyoto or HeLa FRT TO MBD3-GFP cells were grown in Dulbecco’s modified 
essential medium (DMEM) containing 4.5 g/ml glucose, 10% FBS and 1% penicillin/
streptomycin. For all HeLa FRT TO lines, hygromycin and blasticidin were added to 
the medium. 
For SILAC experiments, cells were cultured in SILAC DMEM plus 10% dialyzed se-
rum, 1% glutamine, 1% penicillin/streptomycin, and 30 µg/ml of either light arginine 
(R0) and 73 µg/ml lysine (K0) ór 73 µg/ml heavy lysine (K8) and 30 µg/ml arginine 
(R10) for at least 8 cell divisions. Cells were then expanded and transfected using 
PEI. After 20 hours, cells were harvested for nuclear extract preparation. The stable 
inducible MBD3-GFP HeLa FRT cell line was made by co-transfection of pcDNA5-
FRT-TO-MBD3-GFP and pOG44 containing the flippase into HeLa FRT TO cells, 
after 2 days followed by hygromycin selection.
shRNA knock down
COS7 cells were grown in DMEM F12 containing 4.5 g/ml glucose, 10% FBS and 
1% penicillin/streptomycin. The cells were transfected with lentiviral packaging vec-
tors in combination with an shRNA construct using PEImax. After 24 and 48 hours, 
virus-containing media were collected and concentrated before transducing the tar-
get cells in the presence of polybrene. After another 24 hours, puromycin selection 
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was started to select cells positive for shRNA integration. The knock-down efficiency 
was checked by RT-qPCR and, when possible, by western blot. For some short hair-
pins monoclonals were grown and tested similarly.
Nuclear extract preparation
Nuclear extracts (NE) were prepared as described in Smits et al. [6].
GFP affinity purification
GFP purifications were performed essentially as described by Baymaz et al. [17]. 
When using transient transfection, all cells were transfected to avoid transcriptional 
side effects of PEI or ZMYND8 overexpression. In the HeLa FRT TO system, we 
likewise induced all cells with doxycycline. For the GFP-purifications performed with 
GFP-trap beads (Chromotek) (or RFP-trap beads (chromotek) for GATAD2B-RFP), 
blocked agarose-beads (Chromotek) were used as a negative control. Incubation 
and wash buffers are as described before [17], with 0.25% NP40 during incubation 
and 0.5% NP40 in wash buffer C. On-bead digest was performed using Trypsin. 
Mass spectrometry
Mass spectrometry measurements were performed on an easy nanoHPLC-1000 
(Proxeon) operating a C18 column online with an LTQ-Orbitrap Velos in top15 CID 
mode with an exclusion list of 30 proteins for 30 seconds. An acetonitrile gradient of 
5-80% was applied for 2.5 hours. 
Data analysis
Raw data were analyzed using MaxQuant software package 1.3.0.5  using multi-
plicity 2 for SILAC experiments [24]. We filtered for contaminants and reverse hits 
using Perseus. The normalized forward and reverse ratios were logarithmized and 
significance B was calculated, after which scatterplots were made using R. 
For label-free quantification (LFQ) [18], MaxQuant was applied using multiplicity 1 
and boxes for ‘match between runs’ and ‘iBAQ quantification’ checked. For LFQ 
experiments, LFQ intensities were logarithmized and triplicates were assigned to the 
same group. We then filtered for 3 valid values in at least one group, assuming that 
very specific interactors may only be identified in the triplicates of the specific purifi-
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cation. Missing values were imputed using a normal distribution and default settings. 
A two-sample t-test was performed between the control and the experiment to obtain 
p-values for each protein, after which a volcano plot was made using R. A two-tailed 
ANOVA test was performed to calculate specific outliers when more than two condi-
tions were compared. Stoichiometry determination was performed as described in 
Smits et al. [6] for the ANOVA significant proteins.
Western blot
For western blot analysis, protein samples were applied to SDS-PAGE and transfer-
red to nitrocellulose membrane. The membrane was blocked using 5% skimmed 
milk in TBS-T, after which it was incubated with the primary antibody in milk solution 
for at least one hour and up to overnight incubation. After extensive washing, the 
membrane was incubated with HRP-fused secondary in milk solution for one hour. 
The blot was washed and Enhanced ChemiLuminescence was used to visualize 
proteins on Kodak films. Antibodies used were: RabbitαGFP (Abcam, ab290), Rab-
bitαZMYND8 (Sigma, HPA020949), RabbitαCDK2AP1 V41 (in-house [5]) and Rab-
bitαTAF3 (Bethyl, A302-359A).
Peptide affinity purification
Peptide affinity purifications were performed essentially as described in [25]. Bio-
tinylated peptides were coupled to streptavidin-agarose beads (GE Healthcare), 
after which unbound peptide was washed away using incubation buffer (150 mM 
NaCl, 50 mM Tris-HCl pH 8.0, 0.25% (v/v) NP40, 0.5 mM DTT, 10 µM ZnCl2, 150 
nM TSA and complete protease inhibitors (EDTA free). The peptides were incuba-
ted with NE for 2 hours. Beads were washed extensively and bound proteins were 
eluted using sample buffer and boiling. Proteins were separated on SDS-PAGE and 
western blot was used to visualize the proteins.
ChIP-sequencing
Hela Kyoto cells were seeded on 15 cm dishes. After 24 hours, cells were fixed using 
DSG for 45 minutes, followed by formaldehyde crosslinking for 10 minutes. Cells 
were collected and sonication was used to shear the chromatin into 100-300 bp 
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fragments. Antibodies (RabbitαZMYND8 (Sigma, HPA020949) and RabbitαMBD3 
(Bethyl, A302-528A)) were first coupled to the beads in the presence of BSA, after 
which we incubated this complex with chromatin overnight. Extensive washes were 
performed and DNA was de-crosslinked using a four hour incubation at 65oC. DNA 
was purified using the Qiagen PCR-clean up kit. After this, bound DNA was analyzed 
by deep sequencing on a HiSeq.
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Technological aspects 
	 Since	the	initial	definition	of	the	term	“epigenetics”,	it	has	become	clear	that	
this	phenomenon	does	not	only	 regulate	 the	expression	of	 individual	genes	but	 it	
plays	a	crucial	 role	 in	many	processes,	 ranging	 from	development	 to	disease.	As	
for	many	other	fields,	technological	advancements	have	sky	rocketed	the	epigenetic	
field,	allowing	for	 instance	the	mapping	of	many	different	epigenetic	modifications	
and	 states.	 In	 this	 thesis	 we	 apply	 state-of-the-art	 next-generation	 sequencing	
technologies	 to	address	different	biological	questions.	 In	chapter 2	we	described	
for	 the	 first	 time	 the	 characterization	 of	 the	 epigenome	 and	 the	 transcriptome	 of	
a	 recently	developed	serum-free	culture,	known	 to	 retain	ESCs	 in	a	ground	state	
pluripotency.	 In	chapter 4	we	analyzed	 the	genome-wide	 localization	of	MBD2,	a	
transcription	factor	that	is	part	of	the	NuRD	complex	and	was	not	characterized	in	a	
genome-wide	fashion	at	the	beginning	of	our	study.	Genome-wide	studies	of	NuRD	
components	 proved	 to	 be	 challenging,	which	was	also	 the	 case	 for	MBD2:	 even	
in	 the	most	 recent	 studies	 a	 protein-tagging	 approach	 for	 ChIP-seq	 experiments	
had	to	be	used.	Moreover	we	improved	our	ChIP	protocol	by	adopting	a	two-step	
cross-linking	 procedure,	 which	 stabilizes	 big	 protein	 complexes	 by	 preserving	
protein-protein	interactions	and	increases	reproducibility	and	efficiency	of	the	ChIP	
assay.	With	the	same	protocol	in	chapter 5 we	extended	our	study	to	another	NuRD	
component,	known	as	ZMYND8,	so	 far	poorly	characterized	from	a	genome-wide	
perspective.	In	both	NuRD	component	studies	we	integrated	the	transcription	factor-
binding	data	with	a	set	of	other	epigenetic	marks,	 including	histone	modifications	
and	single	base	resolution	bisulfite	sequencing	to	determine	the	epigenetic	makeup	
at	the	transcription	factor	binding	sites	and	to	gain	insight	into	their	biological	role	in	
vivo.	
The epigenome and transcriptome of ground state pluripotency
 In	 the	 last	 few	 decades	 stem	 cell	 research	 has	 been	 one	 of	 the	 most	
fascinating	areas	of	biology.	ESCs	culturing	conditions	were	established	that	allowed	
the	in	vitro	study	of	early	events	in	the	development	of	an	organism.	In	order	to	culture	
and	maintain	pluripotent	ESCs	in	vitro,	several	external	stimuli	were	required	(bovine	
fetal	calf	serum,	mitotically	inactivated	fibroblasts),	often	resulting	in	heterogeneous	
populations	of	undifferentiated	and	partially	differentiated	cells.	In	more	recent	years	
the	use	of	a	chemically	defined	medium	(2i)	[1]	overcame	these	problems	and	allowed	
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propagation	of	highly	homogenous	populations	of	pluripotent	cells,	establishing	what	
has	been	referred	to	as	the	naïve	or	ground-state	pluripotency.	
	 The	aim	of	chapter 2	was	 to	understand	at	 the	molecular	 level	 the	main	
differences	between	ground	state	pluripotent	cells	(2i)	and	standard	serum	cultured	
cells.	We	profiled	 some	of	 the	main	histone	modifications	 related	 to	 transcription	
activation/repression	 and	 the	 whole	 transcriptome	 in	 both	 culture	 conditions.	
Decreased	expression	of	lineage-affiliated	genes	in	2i	suggested	that	multilineage	
priming	 is	 not	 an	 intrinsic	 feature	 of	 ground	 state	 pluripotency	 and	 rather	 a	
consequence	 of	 external	 culture	 stimuli.	 Further	 support	 for	 this	 conclusion	 was	
the	fact	that	both	culture	conditions	displayed	similar	differentiation	potential.	In	2i,	
decreased	 levels	of	H3K27me3	 repressive	mark	at	promoters	of	 lowly	expressed	
genes	did	not	result	in	the	anticipated	increase	in	transcription.	The	decreased	level	
of	H3K27me3	resulted	in	a	decrease	in	the	number	of	bivalent	promoters,	since	in	
both	conditions	H3K4me3	levels	were	comparable.	This	finding	challenged	the	role	
of	PRC2	as	the	main	repressive	complex	in	mouse	embryonic	stem	cells,	keeping	
lineage-affiliated	 genes	 in	 a	 poised	 state.	 It	 has	 recently	 been	 shown	 [2]	 that	 a	
PCGF1/PRC1	variant	is	recruiting	PRC2	to	drive	formation	of	the	polycomb	domain,	
therefore	contesting	the	general	view	that	PRC1	recruitment	is	depending	on	prior	
PRC2	 nucleation	 and	H3K27me3	 deposition	 [3,	 4].	Although	we	 did	 not	 observe	
differences	in	transcription	of	canonical	PRC1	components	between	2i	and	serum	it	
would	be	interesting	to	further	assess	whether	a	specific	PRC1	variant,	not	analysed	
in	 our	 experiments,	may	 account	 for	 the	 differences	 we	 observed	 in	 H3K27me3	
deposition.	
	 An	 obvious	 question	 arising	 from	 our	 findings	 is:	 what	 is	 the	 molecular	
mechanism	 regulating/repressing	 transcription	 of	 lineage-affiliated	 genes	 in	 2i?	
Surprisingly	 a	 subsequent	 study	 from	our	 and	 other	 labs	 [5-7]	 showed	 that	DNA	
methylation,	 generally	 associated	 to	 transcriptional	 silencing,	 is	 also	 drastically	
reduced	in	2i	and	much	closer	to	ICM	and	naïve	epiblast	(E3.5-E4.5)	levels	unlike	
that	 of	 serum	cells.	 	Counteracting	 the	global	 reduction	of	 epigenetic	 repression,	
we	 found	 that	 2i	 cells	 display	 increased	 levels	 of	 RNA	 polymerase	 II	 pausing	 at	
developmental	genes,	which	might	represent	a	key	regulatory	mechanism,	ensuring	
a	 more	 rapid	 gene	 induction	 response.	 More	 experiments	 will	 be	 required	 to	
elucidate	the	mechanisms	behind	increased	pausing.	Since	mESCs	maintained	in	
2i	are	the	closest	in	vitro	approximation	to	the	epiblast	cells	from	the	ICM	(E4.5)	[8]	
it	would	be	of	great	interest	to	assess	whether	the	same	can	be	obtained	for	human	
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ESCs	(hESCs).	 	 It	 is	known	 that	 for	hESC,	2i	does	not	shield	 from	differentiation	
triggers,	however,	a	recent	study	identified	a	cocktail	of	5	kinase	inhibitors	inducing	
the	generation	of	human	pluripotent	cells	associated	to	naïve	pluripotency	of	human	
preimplantation	 embryo	 (in	 vivo)	 that	 closely	 resemble	mouse	naïve	 pluripotency	
[9].	 Several	 aspects	 still	 limit	 the	 above-mentioned	 culture	 conditions	 from	 being	
optimal	 (linked	mainly	 to	 dependency	on	extrinsic	 stimuli,	 slow	proliferation	 rates	
and	 absence	 of	 functional	 assays	 like	 chimera	 formation)	 and	 improvements	will	
be	needed.	Nevertheless	the	capture	of	human	naïve	pluripotency-like	state	in	vitro	
sheds	new	light	on	the	molecular	underpinning	of	pluripotency	and	holds	potential	
benefits	for	future	biomedical	research.
 
MBD2 mediating transcriptional repression?
	 DNA	 	methylation	was	 the	first	epigenetic	modification	discovered	and	 its	
function	is	still	subject	to	intense	studies.	The	advent	of	next	generation	sequencing	
(NSG)	 technology	 allowed	 the	 generation	 of	 maps	 of	 DNA	 methylation	 at	 base	
resolution	and	shed	new	light	on	dynamics	and	distribution	of	this	epigenetic	mark.	
Most	of	the	CpGs	in	mouse	and	human	are	methylated,	with	the	exception	of	CGIs	
and	active	promoters.	DNA	methylation	at	CpG	rich	promoters	has	been	associated	to	
transcriptional	repression	in	the	past,	however	the	exact	mechanism	is	still	debated.	
MBPs	are	 thought	 to	mediate	 this	 repression	mechanism,	 by	 binding	methylated	
DNA	 and	 recruiting	 co-repressor	 complexes,	 however	 several	 observations	 do	
not	appear	to	support	 this	model.	First	of	all	deletion	of	 individual	MBPs	(with	the	
exception	 of	MBD3)	 is	 not	 embryonic	 lethal	 and	 does	 not	 lead	 to	 reactivation	 of	
methylated	promoters	[10],	suggesting	potential	redundant	functions	within	MBPs.	
However,	systematic	studies	of	combined	knockout	for	more	MBPs	have	not	been	
described	so	far	and	could	be	an	interesting	approach	to	unravel	redundancy.	
	 Recent	studies	mapping	MBPs	binding	genome	wide	in	vivo	revealed	that,	
with	the	exception	of	MBD3,	methylation	density	seems	to	be	the	main	determinant	
for	binding	at	different	genomic	 regions	 (e.g	promoters,	enhancers,	gene	bodies)	
[11,	12].	Surprisingly	for	some	MBPs,	as	for	MBD2,	only	a	very	small	fraction	of	the	
binding	sites	seems	to	co-localize	with	NuRD	components	like	HDAC2	and	CHD4	
[11]	genome	wide.	Moreover	it	has	been	shown	that	the	interaction	with	the	NuRD	
complex	 is	 essential	 for	 the	 binding	 of	MBD2	 to	 a	 small	 subset	 of	 unmethylated	
loci.	Therefore	the	model	suggesting	that	MBD2	binds	methylated	DNA	and	recruits	
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NuRD	in	order	to	deacetylate	and	repress	transcription	should	be	revisited.	The	role	
of	NuRD	itself	has	been	recently	debated,	since	it	was	initially	considered	as	a	co-
repressor	complex,	but	genome	wide	studies	have	shown	its	presence	at	actively	
transcribed	 regions,	 challenging	 its	 merely	 repressive	 function	 and	 suggesting	 a	
multifaceted	role.	
	 In	chapter 4 we	studied	 the	genome-wide	 localization	of	MBD2,	using	a	
tagged-protein	approach.	In	line	with	other	reports	we	found	MBD2	primarily	localized	
at	highly	methylated	loci	but	a	subset	of	its	binding	sites	was	coinciding	with	active	
marks.	The	discrete	position	of	MBD2	at	1kb	downstream	the	transcription	start	sites	
(TSS)	of	this	subset	of	lowly	active	promoters	prompted	us	to	investigate	whether	
Pol2	elongation	was	affected,	 however	we	 could	not	 clearly	 link	 the	 transcription	
state	of	these	genes	with	MBD2	binding.	
	 A	 very	 remarkable	 finding	 from	 chapter 4	 was	 the	 correlation	 between	
hypermethylation	of	MBD2	binding	sites	in	MCF-7	and	in	a	large	cohort	of	primary	
breast	 cancers.	 We	 hypothesize	 that	 MBD2	 is	 likely	 to	 bind	 those	 locations	 in	
primary	 cancers	 and	might	 contribute	 to	 their	 regulation	 of	 transcription.	 Further	
experiments	will	be	needed	to	verify	first	of	all	the	actual	presence	of	MBD2	at	those	
sites	and	second	its	potential	role	in	cancer	etiology.	In	this	direction	a	recent	study	
pointed	 to	 a	 correlation	 between	MBD2	deposition	 and	oncogenic	 transformation	
in	a	model	of	human	mammary	cells	[13].	Even	though	the	observed	redistribution	
of	MBD2	after	oncogenic	transformation	could	not	be	fully	explained	by	local	DNA	
methylation	changes,	MBD2	deposition	mainly	occurred	at	methylated	DNA	regions.	
The	mechanisms	 triggering	MBD2	 redistribution	 during	 oncogenic	 transformation	
and	the	potential	involvement	of	other	factors	remain	to	be	elucidated.	It	would	be	
relevant	to	extend	our	analysis	to	a	cohort	of	primary	tumors	in	order	to	gain	support	
for	 our	 assumptions	 that	 the	 binding	 of	MBD2	 occurs	 to	 hypermethylated	 loci	 in	
cancer	and	possibly	contribute	to	regulate	their	transcription.	Unfortunately	technical	
aspects	for	the	detection	of	endogenous	MBD2	still	remain	a	limiting	factor.	
Zmynd8: a bridge for NuRD to hypomethylated loci? 
	 In	 chapter 5	 we	 set	 out	 to	 address	 which	 factor	 might	 recruit	 NuRD	 to	
hypomethylated/active	loci.	ZMYND8	was	previously	identified	as	a	substochiometric	
interactor	of	the	NuRD	complex	[14-16];	here	we	show	that	it	directly	recruits	NuRD	
through	its	MYND	domain.	Interestingly	a	recent	study	confirmed	this	finding	[17],	
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identifying	 ZMYND8	 as	 a	 novel	DNA	 damage-response	 (DDR)	 factor	 that	 recruit	
NuRD	via	CHD4	to	damaged	chromatin	through	its	MYND	domain.	This	finding	may	
not	 be	 that	 surprising	 since	 some	NuRD	 subunits	 seems	 to	 have	 a	 role	 in	DNA	
damage	response	[18-21]	and	a	recent	screen	 identified	ZMYND8	as	a	reader	of	
formylcytosine	[22],	a	known	substrate	of	the	base	excision	repair	machinery.	
	 Our	 ChIP-seq	 analysis	 for	 ZMYND8	 and	 MBD3	 showed	 that	 they	
preferentially	bind	hypomethylated	active	promoters	and	enhancers,	sharing	many	
binding	sites,	however,	we	still	do	not	know	whether	this	might	just	be	co-localization	
event	or	a	real	functional	link.	One	way	to	shed	light	is	to	assess	whether	recruitment	
of	MBD3	to	its	target	sites	is	lost	upon	ZMYND8	knockout.	It	will	be	interesting	to	
perform	ChIP-seq	for	MBD3	and	ZMYND8	in	either	ZMYND8	or	MBD3	knockout	and	
include	more	NuRD	subunits	in	our	ChIP	experiments.	
	 Curiously	the	study	from	Gong	et	al	[17]	also	shows	that	recruitment	of	NuRD	
through	ZMYND8	requires	transcriptionally	active	sites	of	double	strand	brake	(DSB)	
in	order	to	promote	repression	(of	a	reporter).	They	identify	CHD4	as	the	direct	link	
of	ZMYND8	to	NuRD.	Another	intriguing	question	is	whether	recruitment	of	NuRD	
to	active	sites	would	be	generally	impaired	in	the	absence	of	ZMYND8.	In	order	to	
answer	 this	 question,	ZMYND8	knockout	 experiment	 followed	by	RNA-seq	might	
give	 some	 informative	 answers.	 Moreover	 the	 putative	 transcriptional	 repression	
activity	 of	 NuRD	 itself	 should	 be	 properly	 quantified	 in	 the	 presence/absence	 of	
ZMYND8.	
	 Notably	ZMYND8	has	recently	been	identified	as	a	fusion	gene	with	RelA	
in	a	case	of	acute	erythroid	leukemia	[23],	but	the	molecular	mechanism	triggered	
by	this	fusion-gene	is	not	clear.	It	would	be	interesting	to	study	whether	also	in	this	
system	NuRD	plays	a	critical	role	and	whether	it	is	still	recruited	by	the	fusion	protein.	
CONCLUSIONS
	 In	summary	in	this	thesis	we	characterize	for	the	first	time	the	transcriptional	
and	 epigenetic	 base	 of	 ground	 state	 pluripotency,	 changing	 previous	 statements	
based	 on	 heterogeneous	 culture	 conditions	 and	 providing	 an	 important	 basis	 for	
further	studies	also	in	human	stem	cells.	We	show	that	metastability	and	bivalency	
are	 not	 prerequisites	 of	 pluripotency	 and	 possible	 alternative	mechanisms	might	
suppress	transcription	of	lineage-affiliated	genes.	Further	studies	will	be	needed	to	
decipher	how	transcription	regulation	occurs	in	an	apparently	permissive	epigenetic	
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landscape.	
	 We	 further	describe	 the	 in	vivo	genome-wide	binding	pattern	of	MBD2,	a	
MBP	 belonging	 to	 the	 NuRD	 complex	 previously	 only	 characterized	 in	 vitro.	We	
show	that	its	genomic	occupancy	correlates	with	highly	methylated	loci,	confirming	
properties	described	in	in	vitro	assays.	We	also	identified	a	small	subpopulation	of	
binding	sites	at	lowly	transcribed	promoters	decorated	with	active	epigenetic	marks.	
Our	data	is	 in	line	with	another	study	[11]	suggesting	that	recruitment	of	MBD2	to	
active	sites	depends	on	 its	 interaction	with	NuRD,	whereas	all	 the	 remaining	 loci	
seem	not	to	co-localize	with	well-known	NuRD	components.	
	 We	 finally	 extend	 the	 ChIP-seq	 analysis	 to	 ZMYND8,	 another	 NuRD	
component,	 which	 we	 found	 localized	 at	 active	 hypomethylated	 loci	 and	 likely	
recruits	NuRD	to	those	sites.	A	combination	of	quantitative	proteomic	and	genome	
wide	studies	is	the	key	for	deciphering	the	interaction	within	chromatin-remodeling	
complex	components	and	 the	dynamics	of	 their	 recruitment	 to	chromatin.	Further	
studies	will	clarify	 the	different	aspects	 that	play	a	role	 in	 recruitment	of	NuRD	to	
active	sites,	together	with	the	involvement	and	interplay	of	any	other	component.
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SAMENVATTING
De genetische informatie gecodeerd in het DNA van een cel kan niet verklaren hoe 
verschillende fenotypen gegenereerd kunnen worden. Epigenetica, wat letterlijk 
“rondom” genetica betekent, bestudeert alle mechanismen die de DNA sequentie 
niet veranderen, maar wel verantwoordelijk zijn voor de translatie van het genoom 
in verschillende fenotypen van cellen. Het gebruik van next generation sequencing 
(NGS) technieken heeft een grote impact gehad op het epigenetisch vakgebied. 
NGS maakt het mogelijk de lokalisatie van meerdere epigenetische modificaties 
(e.g. DNA methylatie, histon modificaties) door het gehele genoom (genoomwijd) 
te bepalen, en daarmee om een indexering te maken van wat het epigenoom wordt 
genoemd. In deze thesis passen wij state-of-the-art next-generation sequencing 
technieken in verschillende biologische contexten.
 In hoofdstuk 1 vat ik de huidige kennis over epigenetische mechanismen 
samen met een specifieke focus op hun betrokkenheid bij embryonale pluripotentie 
en ontwikkeling. 
 Naïeve pluripotentie wordt hier geïntroduceerd en verder uitgewerkt in 
hoofdstuk 2. In dit hoofdstuk beschrijven we nauwkeurig de epigenetische status 
van embryonale stamcellen gekweekt in serumvrije medium, aangeduid als “2i”. 2i 
staat erom bekend dat embryonale stamcellen hun naïeve pluripotentie houden. 
Onze studie laat zien dat naïeve pluripotentie gekarakteriseerd wordt door een 
verminderde transcriptie van differentiatie-geassocieerde genen, maar tegelijkertijd 
ook door verminderde niveaus van H3K27me3 repressieve markering bij promotors 
van laag tot expressie komende genen. Zodoende schijnen multilineage priming en 
bivalentie een consequentie te zijn van externe kweek stimuli.
Naast de epigenetische blauwdruk van naïeve pluripotentie is een andere focus van 
deze thesis gecentreerd rond een specifieke klasse van lezers van DNA methylatie, 
bekend als methyl-CPG binding proteins (MBPs). 
 Hoofdstuk 3 focust op 2 leden van deze familie: MBD2 en MBD3. We geven 
een overzicht van de state-of-the-art in het onderzoek betreffende hun genoomwijde 
binding alsmede hun opkomende rol in gen regulatie. Deze twee eiwitten behoren tot 
erg gelijksoortige (NuRD) complexen; Desalniettemin vertonen zij erg verschillende 
functies. 
 In hoofdstuk 4 bestuderen we de genoomwijde bindingsplekken van 
MBD2. De capaciteit van MBD2 om gemethyleerd DNA te binden werd al jaren 
Samenvatting
179
geleden gedemonstreerd in vitro, maar pas recent ook in vivo. We bevestigen dat 
MBD2 primair gelokaliseerd is bij zeer gemethyleerde loci, maar ook – in lijn met 
recente berichtgevingen – dat een subset van zijn bindingsplaatsen co-lokaliseert 
met epigenetische markeringen van actieve transcriptie. Bovendien suggereert 
de correlatie tussen onze MBD2 bindingsplekken en de toegenomen methylatie 
op diezelfde plekken in primaire kankers dat MBD2 wellicht een rol heeft in hun 
transcriptionele regulatie tijdens oncogene transformatie. 
 Aangezien bekend is dat een kleine fractie van de NuRD bindingsplekken 
plaatsvind op hypogemethyleerde loci, focussen we in hoofdstuk 5 op een andere 
component van het NuRD complex: ZMYND8. Door een gecombineerde aanpak van 
interactie studies en genoomwijde profilering hebben we we meer inzicht verkregen 
in ZMYND8 sequentie-specifieke rekrutering van NuRD en hun co-lokalisatie bij 
actieve, hypogemethyleerde plekken.
 In Hoofdstuk 6 bediscussieer ik het in dit proefschrift gepresenteerd werk 
in het licht van ander recente onderzoek, en doe ik suggesties voor toekomstig 
onderzoek.
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SUMMARY
The genetic information encoded in the DNA of a cell can in itself not explain how 
different cellular phenotypes can be generated. Epigenetics, literally meaning 
“around” genetics, includes all the mechanisms that do not change the DNA sequence, 
but can account for the translation of the genome into the different phenotypes of 
cells. The use of next generation sequencing (NGS) technologies has had a great 
impact on the epigenetic field, because it allows depicting the distribution of several 
epigenetic modifications (e.g. DNA-methylation, histone modifications) throughout 
the whole genome (genome-wide), thereby indexing what we define the epigenome. 
In this thesis we applied state-of-the-art next-generation sequencing technologies in 
various biological contexts. 
 In chapter 1 I summarize the current knowledge on epigenetic mechanisms 
with a specific focus on their involvement in embryonic pluripotency and development. 
 Ground state pluripotency is also introduced here and further unraveled in 
chapter 2. In that chapter, we dissect the epigenetic mechanisms of ESCs maintained 
in serum-free culture referred as “2i”, known to keep ESCs in a ground state of 
pluripotency. Our study reveals that ground state pluripotency is characterized by 
decreased transcription of lineage affiliated genes. Counterintuitively we detected 
decreased levels of the H3K27me3 repressive mark at the promoters of lowly 
expressed genes. Altogether, multilineage priming and bivalency appear to be a 
consequence of external culture stimuli.
Next to the epigenetic blueprint of ground state pluripotency, another focus of this 
thesis is on a specific class of readers of DNA methylation, known as methyl-CpG 
binding proteins (MBPs).
 Chapter 3 focuses on 2 members of this family: MBD2 and MBD3. We 
reviewed the current knowledge on genome-wide binding features together with 
their emerging roles in gene regulation. These two proteins belong to very similar 
(NuRD) complexes; nevertheless they display very different functions. 
 In chapter 4 we study the genome-wide profile of MBD2, whose ability to 
bind methylated DNA had been demonstrated in vitro already for a long time, but 
only recently proven in vivo as well. We confirm that MBD2 primarily localizes at 
highly methylated loci and -in line with recent reports- a subset of its binding sites 
co-localize with epigenetic marks of active transcription. Moreover the correlation 
between our MBD2 binding sites on one hand and increased methylation at the 
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same sites in primary cancers on the other hand might suggest that MBD2 has a role 
in their transcriptional regulation during oncogenic transformation.
 Since a small fraction of NuRD binding sites is reported to occur at 
hypomethylated loci, we focused on another NuRD complex component (ZMYND8) 
in  chapter 5. Through a combined approach of interaction studies and genome-
wide profiling we gain more insight into ZMYND8 sequence-specific recruitment of 
NuRD and their colocalization at active, hypomethylated sites. 
 In chapter 6 I discuss  the work presented in this thesis in the light of other 
recent research, and provide an outlook for future research.  
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